A Competency-Based Guide to Curriculum Development






TABLE OF CONTENTS

| TABLE OF CONTENTS | 2 |
|--|----|
| INTRODUCTION | 3 |
| HOW TO USE THIS CURRICULUM OUTLINE | 4 |
| I. MEDICAL KNOWLEDGE | 5 |
| II. PATIENT CARE | 17 |
| III. PRACTICE-BASED LEARNING AND IMPROVEMENT | 21 |
| IV. SYSTEMS-BASED PRACTICE | 22 |
| V. INTERPERSONAL AND COMMUNICATION SKILLS | 24 |
| VI. PROFESSIONALISM | 25 |
| APPENDIX A. RHEUMATOLOGY MILESTONES 2.0 | 27 |
| APPENDIX B. RHEUMATOLOGY ENTRUSTABLE PROFESSIONAL ACTIVITES | 55 |
| APPENDIX C. RHEUMATOLOGY CURRICULAR MILESTONES | |
| APPENDIX D. RHEUMATOLOGY TOOLBOX: ACTIVITIES AND ASSESSMENTS | |

INTRODUCTION

The subspecialty of rheumatology includes a wide array of autoimmune, inflammatory, and non-inflammatory conditions that affect the musculoskeletal and other organ systems. The purpose of rheumatology training programs is to 1) train fellows to be accomplished practitioners and consultants in the rheumatic diseases, and 2) encourage the professional and scholarly attitudes and approaches of a competent subspecialist that are needed to maintain an understanding of current concepts in rheumatology as advances occur.

This Core Curriculum Outline updates the previous ACR Core Curriculum Outline for Program Directors (2006, 2015) and is designed to reflect the Next Accreditation System (NAS) and the importance of competency-based training and assessment in graduate medical education, as defined by the Accreditation Council for Graduate Medical Education (ACGME). Also included in this core curriculum outline are:

Rheumatology Milestones 2.0 (Appendix A) Rheumatology Entrustable Professional Activities (EPAs) (Appendix B) Rheumatology Curricular Milestones (Appendix C) Rheumatology Toolbox: Activities and Assessments (Appendix D)

The updated curriculum outline continues to be organized by the six ACGME core competencies. These are:

Medical Knowledge Patient Care Practice-based Learning and Improvement Systems-based Practice Interpersonal and Communications Skills Professionalism

The two major sections of Basic Science and Clinical Science are incorporated into the medical knowledge section, which was updated in December 2020. Clinical aspects of these areas reside in the patient care section. Those aspects of the Core Curriculum that pertain to practice-based learning and improvement, systems-based practice, interpersonal and communication skills and professionalism are expanded into their own individual major sections. The purpose of specifically highlighting the core competencies in the Core Curriculum Outline is to clarify their essential components. The description of how and where they are acquired in the course of fellowship training, projected trainee performance benchmarks, and suggestions for tools to measure that performance are delineated within the Rheumatology Curricular Milestones (Appendix C, 2015) and Rheumatology Toolbox (Appendix D), the latter containing the educational activities and evaluation tools employed during fellowship training.

A major update to this 2020 Curriculum Outline is inclusion of pediatric rheumatology within the outline rather than as an appendix and includes a minimum set of core knowledge in pediatric rheumatology for the adult trainee. The ACGME suggests that "programs with the qualified faculty and facilities provide training in pediatric rheumatic disease." The ACR recognizes that, because of the worldwide shortage of pediatric rheumatologists, many internist rheumatologists in clinical practice will be called upon to evaluate and treat children. The Core Curriculum reflects the ACR goal that every rheumatology fellow should have familiarity with pediatric rheumatic diseases, whether or not they have the opportunity to rotate through a pediatric rheumatology clinic. Because reading is not a substitute for direct experience, training programs are encouraged to find opportunities for their fellows to see patients in a pediatric rheumatology clinic. This outline is consistent with the requirements of the ACGME Review Committee for training in rheumatology and serves as a guide for Training Program Directors and fellows in meeting these requirements.

The Core Curriculum Outline presents a comprehensive view of the components of a competency-based training program in rheumatology and is meant to provide a detailed guide for Program Directors to use in developing their own fellowship training curriculum. Individual training programs are expected to adapt this outline for their own curriculum and may reflect their particular areas of expertise and resources. This document is meant to be a practical resource for Program Directors to provide detailed descriptions of general competencies in rheumatology and provide tools for performance markers and assessments in these areas (see Rheumatology Curricular Milestones and Rheumatology Toolbox, Appendix C and Appendix D, respectively).

HOW TO USE THIS CURRICULUM OUTLINE

This Curriculum Outline divides each competency into several sections. A <u>Definition</u> of the competency in the context of rheumatology training is provided. The <u>Essential Components</u> of each competency are then listed and described. These components can be used to provide the rationale for selected training activities. Documentation of a competency-based curriculum involves describing the specific educational activities through which the training program works to develop and assess the six ACGME core competencies in its trainees during the course of the fellowship training program. According to the ACGME Program Requirements for Graduate Medical Education in Rheumatology, while the description of each educational activity (e.g., rotation, conference, or research activity) should delineate its goals and objectives, fellow responsibilities by year of training, and level of fellow supervision, the structure and methods used to evaluate the development of competency and the means by which the Program Director documents the educational activity components of the curriculum are all at the discretion of the individual fellowship program and may vary widely from program to program. Several Appendices have been included to provide milestones and tools that can be used to develop and document a competency-based curriculum.

I. MEDICAL KNOWLEDGE

The subspecialty of rheumatology includes a wide array of autoimmune, inflammatory, and non-inflammatory conditions that affect the musculoskeletal and other organ systems. A working knowledge of the basic and clinical sciences that relate to musculoskeletal and rheumatic disease is fundamental to the practice of rheumatology. Recognition of normal and pathogenic processes of the immune system form the basis of reliable diagnosis and the development and use of an increasingly sophisticated range of immunomodulatory treatments for the rheumatic diseases.

Similarly, knowledge of the basis for and use of laboratory tests of immune activity is a principal asset of the practicing rheumatologist. Rheumatology trainees must also have practical understanding of the approaches and modalities used by other specialists and health professionals (Nurses, Nurse Practitioners, Physician Assistants, etc.) for the treatment of rheumatic diseases in order to manage the care of their patients effectively. Training programs must teach and emphasize the cognitive skills that are necessary to apply this detailed knowledge to problem solving for diagnosis, treatment and research of the rheumatic diseases.

DEFINITION

Medical knowledge refers to the assimilation of established and evolving biomedical, clinical, and cognate sciences, and to the application of this knowledge to patient care.

ESSENTIAL COMPONENTS

BASIC SCIENCES

- A. Anatomy and biology of musculoskeletal tissues: for each tissue, consider the embryology, development, biochemistry and metabolism, structure, function, and classification
 - 1. Connective tissue cells, including fibroblasts, chondrocytes, osteoblasts/osteocytes
 - Extracellular matrix (ECM) molecules: collagens (fibrillar collagens and minor collagens), proteoglycans/aggrecan, elastin, matrix glycoproteins. Enzymatic degradation of ECM (metalloproteases).
 - 3. Joints and joint tissues: diarthrodial joints, intervertebral discs, growth plate, synovium, cartilage (hyaline, elastic, and fibrocartilage), subchondral bone, meniscus.
 - 4. Bone: development, structure, turnover and remodeling (including the role of osteoclasts, osteoclasts, osteocytes, as well as hormonal and cytokine regulation)
 - 5. Muscle, tendons, ligaments.
 - 6. Vasculature and endothelium
 - 7. Skin
- B. Immunology
 - 1. Anatomy and cellular elements of the immune system
 - a. Lymphoid organs
 - i. Bone marrow, thymus, lymph nodes and tertiary lymph tissues
 - ii. Gross and microscopic anatomy, structure and function
 - b. Specific cells: for each cell type, the ontogeny, structure, phenotype, function, and major activation markers/receptors
 - i. Lymphocytes: T cells including naive, memory, and activated (Th1, Th2, Th17, regulatory): B cells: and innate lymphocytes
 - ii. Antigen presenting cells: dendritic cells, monocytes/macrophages
 - iii. Other cells: Neutrophils, eosinophils, natural killer
 - (NK) cells, mast cells, epithelial cells, endothelial cells, platelets, fibroblasts
 - 2. Immune and inflammatory mechanisms
 - a. Innate mechanisms
 - i. Acute phase reactants and enzymatic defenses

- ii. Complement pathways, activation, and regulation
- iii. Toll-like (TLR) and other pattern recognition receptors (PRR)
- iv. Inflammasome components, activation, and function
- v. Neutrophil extracellular traps (NETosis)
- vi. NK cell activation and regulation
- vii. Interactions with adaptive immune mechanisms
- b. Adaptive mechanisms
 - i. T cells: development, genetic basis of T cell receptor diversity, molecular basis of antigen recognition and cellular activation
 - ii. B cells: development, B cell receptor and antibody structure and genetic basis of diversity, cellular activation and effector functions Antigens: types, structure, processing, presentation, and elimination
 - iii. Major histocompatibility complex: structure, function, nomenclature, and immunogenetics
 - iv. Cellular activation and regulation: mechanisms of activation and suppression of function (e.g. T cell and B cell interactions via CD28:CD80/86)
- 3. Initiation of an immune response
 - a. Immune cell trafficking: adhesion molecules, chemokines
 - b. Inflammatory mediators: origin, structure, effect, site of action, metabolism, and regulation
 - c. Cytokines: origin, structure, effect, site of action, metabolism, regulation, signal transduction, and gene activation
- 4. Types of immune responses
 - a. Antibody-mediated: opsonization, complement fixation, and antibody dependent cellular cytotoxicity
 - b. Cell-mediated: cells and effector mechanisms in cellular cytotoxicity, granuloma formation, and delayed type hypersensitivity
 - c. IgE-mediated: acute and late-phase reactions
 - d. Mucosal immunity and the microbiome
 - e. Pathologic immune responses: immune complex-mediated (physicochemical properties and clearance of immune complexes), graft versus host response, abnormal apoptosis
- 5. Immunoregulation
 - a. Tolerance: mechanisms of central and peripheral tolerance, including clonal selection, deletion, and anergy
 - b. Cell-cell interactions: help and suppression; collaboration among cells for control of the immune response
 - c. Autoimmunity: pathogenesis of systemic and organ specific autoimmunity
 - d. Idiotype networks: inhibition and stimulation
- C. Crystalline disease metabolism
 - 1. Purine and uric acid metabolism
 - a. Purine: biochemistry, synthesis, and regulation
 - b. Uric acid: origin, elimination, and physicochemical properties
 - c. Purine pathway enzyme deficiencies and immunodeficiency: ADA, PNP
 - 2. Calcium-based crystal metabolism
 - a. Crystals: factors affecting formation, induction of inflammation
 - b. Genetic abnormalities contributing to crystal formation
- D. Genetics and epigenetics: monogenic vs. polygenic, single nucleotide polymorphisms, DNA methylation, histone modification
- E. Biomechanics of bones, joints, and muscles: principles of kinesiology of peripheral/axial joints and gait and how alterations in biomechanics contribute to musculoskeletal disorders
- F. Neurobiology of Pain
 - 1. Peripheral afferent nociceptive pathways (including joint innervation by nociceptors and proprioceptors).
 - 2. Central processing of nociceptive information (dorsal horn and supraspinal levels)
 - 3. Peripheral and central sensitization (hyperalgesia, allodynia, temporal summation)
 - 4. Acute vs. chronic pain.
 - 5. Biopsychosocial model of pain

CLINICAL SCIENCES

A. Rheumatic Diseases

For each disease, acquire knowledge of the epidemiology, genetics, disease pathogenesis, natural history, clinical expression (including clinical subtypes), pathology.

- 1. Rheumatoid arthritis
- 2. Spondyloarthritis
 - a. axial and peripheral: ankylosing spondylitis, reactive arthritis, psoriatic arthritis, inflammatory bowel disease-associated arthritis
 - b. arthritis associated with acne and other skin diseases like hidradenitis suppurativa, synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, and undifferentiated spondyloarthritis
 - c. non-radiographic axial spondyloarthritis
- 3. Lupus and antiphospholipid syndrome: drug-related; anti-phospholipid antibody syndrome primary and secondary
- 4. Scleroderma and other fibrosing skin disorders
 - a. Limited and Diffuse systemic sclerosis
 - b. Localized Scleroderma
 - c. Other fibrosing skin disorders (eosinophilic fasciitis, eosinophilia-myalgia syndrome, nephrogenic systemic fibrosis, scleromyxedema, scleredema of Buschke)
- 5. Other connective tissue diseases: Sjögren syndrome, mixed connective tissue disease, undifferentiated connective tissue disease, and overlap syndromes
- 6. Systemic vasculitides
 - a. Large vessel: giant cell arteritis/polymyalgia rheumatica, Takayasu arteritis
 - b. Medium vessel: polyarteritis nodosa, Kawasaki disease
 - c. Small vessel: ANCA-associated vasculitis such as granulomatosis with polyangiitis (GPA, formerly Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) and microscopic polyangiitis, anti-glomerular basement membrane disease, cryoglobulinemia, Immunoglobulin A vasculitis (formerly Henoch-Schönlein purpura)
 - d. Other vasculitis syndromes: hypocomplementemic urticarial vasculitis, Behçet disease, Cogan syndrome, cutaneous leukocytoclastic angiitis, primary central nervous system vasculitis
 - e. Miscellaneous: isolated aortitis, vasculitis from systemic disorders, infections, drugs, malignancies
- 7. Crystalline arthropathies: monosodium urate monohydrate (gout), calcium pyrophosphate dihydrate deposition disease, basic calcium phosphate (hydroxyapatite), calcium oxalate
- 8. Immune-mediated inflammatory myositis:
 - a. polymyositis including immune- mediated necrotizing myositis, dermatomyositis, antisynthetase syndrome, inclusion body myositis, myositis associated with other connective tissue diseases
 - b. Other myositis: ocular/orbital myositis, focal/nodular myositis, eosinophilic myositis, granulomatous myositis
- 9. Other autoimmune disease: relapsing polychondritis, panniculitis (lobular or septal [erythema nodosum]), adult-onset Still's disease, IgG4-related disease, retroperitoneal fibrosis, primary Raynaud's disease, neuromyelitis optica, interstitial pneumonia with autoimmune features (IPAF), sarcoidosis, Susac syndrome, palindromic rheumatism, autoimmune disorders associated with checkpoint inhibitors, orbital inflammatory disease, remitting seronegative symmetrical synovitis with pitting edema (RS3PE)
- 10. Autoinflammatory syndromes. See section B.1.h and B.1.i for complete list.
- 11. Inherited muscle diseases
 - a. Metabolic myopathies: glycogen storage diseases, lipid metabolism disorders, mitochondrial myopathies
 - b. Muscular dystrophies
 - c. Muscle channelopathies

- 12. Infectious
 - a. Infectious arthritides: bacterial (non-gonococcal and gonococcal), mycobacterial, spirochetal (syphilis, Lyme), viral (HIV, hepatitis B, hepatitis C, parvovirus, chikungunya, dengue), fungal, parasitic, Whipple disease
 - b. Post-infectious: acute rheumatic fever, arthritis associated with subacute bacterial endocarditis, intestinal bypass arthritis, post-dysenteric arthritides, post-immunization arthritis, other colitis-associated arthropathies
- 13. Metabolic, endocrine, and hematologic disease associated rheumatic disorders
 - a. Endocrine-associated diseases: rheumatic syndromes associated with diabetes mellitus, acromegaly, parathyroid disease, thyroid disease, Cushing disease
 - b. Hematologic-associated diseases: rheumatic syndromes associated with hemophilia, hemoglobinopathies, angioimmunoblastic lymphadenopathy or lymphoma, multiple myeloma, hemophagocytic lymphohistiocytosis/macrophage activation syndrome
- 14. Bone and cartilage disorders
 - a. Osteoarthritis: primary and secondary osteoarthritis
 - b. metabolic bone disease: low bone mass, osteoporosis, osteomalacia, bone disease related to renal disease
 - c. Paget disease of bone
 - d. Avascular necrosis of bone: idiopathic, secondary causes, osteochondritis dissecans
 - e. Others: transient osteoporosis, hypertrophic osteoarthropathy, diffuse idiopathic skeletal hyperostosis
- 15. Hereditary, congenital, and inborn errors of metabolism associated with rheumatic syndromes
 - a. Disorders of connective tissue: Marfan syndrome, osteogenesis imperfecta, Ehlers-Danlos syndrome, pseudoxanthoma elasticum, hypermobility syndrome
 - b. Mucopolysaccharidoses
 - c. Osteochondrodysplasias: multiple epiphyseal dysplasia, spondyloepiphyseal dysplasia
 - d. Inborn errors of metabolism affecting connective tissue: homocystinuria, ochronosis
 - e. Storage disorders: Gaucher disease, Fabry disease
 - f. Immunodeficiency: IgA deficiency, complement component deficiency, SCID and ADA deficiency, PNP deficiency, others
 - g. Others: hemochromatosis, hyperlipidemic arthropathy, myositis ossificans progressiva, Wilson disease, others
- 16. Non-articular and regional musculoskeletal disorders
 - a. Fibromyalgia
 - b. Myofascial pain syndromes
 - c. Axial syndromes: low back pain, spinal stenosis, intervertebral disc disease and radiculopathies, cervical pain syndromes, coccydynia, osteitis condensans ilii, osteitis pubis, spondylolisthesis/spondylolysis, discitis
 - d. Regional musculoskeletal disorders: in addition to bursitis, tendinitis, or enthesitis occurring around each joint, other characteristic disorders occurring at each specific joint site (e.g., shoulder: rotator cuff tear, subacromial bursitis, adhesive capsulitis, impingement syndrome; wrist: ganglion cysts, De Quervain tenosynovitis; trigger fingers/stenosing tenosynovitis, Dupuytren contractures; knee-synovial plica syndrome, internal derangements, popliteal cyst; foot/ankle: plantar fasciitis, achilles tendinitis, Morton neuroma; other: temporomandibular joint syndromes, femoral acetabular impingement, costochondritis)
 - e. Biomechanical/anatomic abnormalities associated with regional pain syndromes: scoliosis and kyphosis, genu valgum, genu varum, leg length discrepancy, foot deformities
 - f. Overuse rheumatic syndromes: occupational, sports, recreational, performing artists
 - g. Sports medicine: injuries, strains, sprains, nutrition, medication issues
 - h. Entrapment neuropathies: thoracic outlet syndrome, upper extremity entrapments, lower extremity entrapments
 - i. Other: peripheral neuropathies (polyneuropathy, small fiber neuropathy), mononeuritis multiplex, complex regional pain syndrome (formerly reflex sympathetic dystrophy), erythromelalgia
- 17. Neoplasms and tumor-like lesions

- a. Benign
 - i. Joints: loose bodies, fatty and vascular lesions, synovial osteochondromatosis, pigmented villonodular synovitis, ganglions
 - ii. Tendon sheaths: fibroma, giant cell tumor, nodular tenosynovitis
 - iii. Bone: osteoid osteoma
- b. Malignant
 - i. Primary: synovial sarcoma, osteosarcoma, chondrosarcoma
 - ii. Secondary: leukemia, myeloma, metastatic malignant tumors
 - Malignancy-associated rheumatic syndromes: carcinomatous polyarthritis, palmoplantar fasciitis, Sweet syndrome, paraneoplastic presentations of rheumatic diseases
- 18. Rheumatic diseases in special populations
 - a. Geriatric population
 - b. Pregnant women
 - c. Dialysis patients
 - d. Transplant patients
- 19. Miscellaneous rheumatic disorders
 - a. Amyloidosis: primary, secondary, hereditary
 - b. Charcot joint
 - c. Multicentric reticulohistiocytosis
 - d. Arthritic and rheumatic syndromes associated with plant thorn synovitis, scurvy, pancreatic disease, primary biliary cirrhosis, drugs, frost bite, and environmental agents
- B. Pediatric rheumatic diseases

Some rheumatic diseases in children and adults can share similar features of pathogenesis, presentation, clinical course, and treatment. These diseases (such as systemic lupus, scleroderma spectrum diseases, the systemic vasculitides, and enteropathic arthritides) are not specifically addressed in this section. Other diseases or specific aspects thereof that are unique or more prevalent in children are included in this outline of knowledge content.

- 1. Rheumatic diseases that occur primarily in children: diagnosis and recognition of similarities and differences to comparable diseases in adults
 - a. Juvenile idiopathic arthritis (JIA)
 - i. Special considerations in pediatric arthritis
 - ii. Exam variations to match developmental status
 - iii. Variable clinical presentations: painless effusions or contractures
 - iv. Variable rates of serologic markers by JIA subtype
 - v. Inflammatory markers may be normal even with active inflammation
 - b. JIA subtypes
 - i. Systemic Onset (Still's disease in adults) (also see autoinflammatory disease below)
 - ii. Oligoarticular
 - Polyarticular (RF positive, RF negative) (polyJIA, RF positive similar to adult RA)
 - iv. Enthesitis-related
 - v. Psoriatic arthritis
 - vi. Undifferentiated arthritis
 - c. Juvenile dermatomyositis
 - d. Kawasaki Disease
 - e. IgA Vasculitis (formerly known as Henoch-Schönlein Purpura, HSP)
 - f. Acute rheumatic fever and post-streptococcal reactive arthritis
 - g. Neonatal lupus syndrome
 - h. Monogenic autoinflammatory diseases:

- Inflammasomopathies: Familial Mediterranean Fever (FMF), hyperimmunoglobulinemia D syndrome (HIDS), tumor necrosis factor receptorassociated periodic syndromes (TRAPS), pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome (PAPA), and cryopyrin associated periodic syndrome (CAPS) including Muckle-Wells syndrome, familial cold autoinflammatory syndrome, and neonatal-onset multisystemic inflammatory disease (NOMID)
- ii. Interferonopathies: STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutieres Syndrome, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, and coatomer protein complex subunit alpha (COPA) syndrome
- Others: deficiency of interleukin-1 receptor agonist (DIRA), deficiency of interleukin-36 receptor antagonist (DITRA), Majeed syndrome, Blau syndrome (NOD2/CARD15), A20 haploinsufficiency (HA20), deficiency of adenosine deaminase 2 (DADA2)
- i. Polygenic autoinflammatory diseases: Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA), chronic recurrent multifocal osteomyelitis (CRMO), and Schnitzler syndrome
- 2. Notable differences, major sequelae and life-threatening complications of rheumatic diseases that are seen in children
 - a. Systemic onset JIA

i.

- i. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (MAS)
- ii. Cardiac tamponade
- iii. Lung disease (pulmonary arterial hypertension, alveolar proteinosis, interstitial lung disease)
- b. ANA+ oligo, polyarticular, and psoriatic JIA
 - Chronic uveitis
- c. Enthesitis-related arthritis
 - i. Some advance to ankylosing spondylitis
 - ii. May be HLA b27 associated
- d. Juvenile dermatomyositis
 - i. Rarely associated with malignancy
 - ii. GI vasculitis
 - iii. Calcinosis
 - iv. Joint contractures
 - v. Dysphagia and aspiration
 - vi. Interstitial lung disease
- e. Kawasaki Disease
 - i. Aneurysms of coronary and other arteries
 - ii. Hemophagocytic lymphohistiocytosis/Macrophage activation syndrome (MAS)
- f. IgA Vasculitis (formerly known as Henoch-Schonlein Purpura, HSP)
 - i. GI- intussusception, intestinal infarction
 - ii. Renal chronic IgA mediated glomerulonephritis
- g. Neonatal lupus syndrome
 - i. Congenital heart block
 - ii. Thrombocytopenia
 - iii. Hepatitis
- 3. Appropriate treatments of the above childhood rheumatic disorders and complications of

treatment

- 4. Non-rheumatic disorders in children that can mimic rheumatic diseases
 - a. Infectious or post-infectious syndromes
 - i. Septic arthritis and osteomyelitis
 - ii. Transient (toxic) synovitis of the hip
 - iii. Post-infectious arthritis and arthralgia including gastrointestinal and GU infections
 - iv. Post-viral myositis
 - b. GI-related autoimmune disorders
 - i. Autoinflammatory bowel disease
 - ii. Celiac disease
 - c. Orthopedic conditions
 - i. Legg-Calve-Perthes disease and other avascular necrosis syndromes
 - ii. Slipped capital femoral epiphysis
 - iii. Spondylolysis and spondylolisthesis
 - iv. Patellofemoral syndrome
 - d. Non-rheumatic pain
 - i. Benign limb pains of childhood ("growing pains")
 - ii. Benign hypermobility syndrome
 - e. Neoplasms
 - i. Leukemia
 - ii. Lymphoma
 - iii. Primary bone tumors (especially osteosarcoma and Ewing sarcoma)
 - iv. Tumors metastatic to bone (especially neuroblastoma)
 - f. Bone and cartilage dysplasias, and inherited disorders of metabolism (Marfan syndrome, osteogenesis imperfecta, Ehlers-Danlos syndrome, pseudoxanthoma elasticum)
- 5. Non-articular and regional musculoskeletal disorders
 - a. Pain amplification syndromes
 - i. Pediatric Fibromyalgia
 - ii. Complex Regional Pain Syndrome (CRPS) type I (also known as Reflex sympathetic dystrophy)
- 6. Special considerations in childhood of rheumatic diseases and treatments
 - a. Disease effects on growth
 - i. Accelerated or decelerated growth of limbs or digits affected by arthritis (muscle atrophy, leg length discrepancy)
 - ii. Altered growth of mandible in TMJ arthritis
 - iii. Short stature and failure to thrive
 - b. Regular surveillance for uveitis in JIA
 - i. Asymptomatic nature of most JIA-associated uveitis
 - ii. Screening schedule based on age of JIA onset, JIA type, duration of disease, ANA status
 - iii. Potential sequelae: Cataracts, glaucoma, synechiae, vision loss
- 7. Drugs
 - a. FDA approved drugs for childhood rheumatic diseases
 - b. Pediatric dosing and special considerations in terms of pharmacokinetics and drug metabolism

- c. Off label use of medications may be necessary
- 8. Child-specific side effects of chronic glucocorticoid treatment
 - a. Growth retardation
 - b. Delay of puberty
- 9. Physical and occupational therapy
 - a. Exercises
 - b. Splinting
- 10. Psychosocial and developmental issues
 - a. Peer and sibling interaction
 - b. Family adjustment
 - c. School accommodations for disability
 - d. School and recreational activities
 - e. Delayed or regressed developmental milestones
- 11. Transition to adulthood
 - a. Transition of care
- C. Therapeutic modalities and strategies
 - 1. Pharmacology: for each medication, the dosing, pharmacokinetics, metabolism, mechanisms of action, side effects, drug interactions, adherence issues, costs, and use in specific patient populations, such as chronic kidney disease and including fertile, lactating, and pregnant women and fertile men as well as across the age spectrum
 - a. Nonsteroidal anti-inflammatory drugs
 - b. Glucocorticoids: topical, intra-articular, systemic
 - c. Systemic anti-rheumatic drugs
 - i. DMARDs
 - (1) Anti-malarials
 - (2) Anti-inflammatory
 - (3) Anti-metabolites
 - (4) Alkylating agent
 - ii. Calcineurin inhibitors
 - iii. Biologic agents and biosimilar agents
 - (1) Interleukin inhibitors (1, 5, 6, 12, 17, 23)
 - (2) Tumor necrosis factor inhibitors (soluble or monoclonal)
 - (3) T cell co-stimulatory inhibitors
 - (4) B cell depletion therapy
 - (5) Inhibitor of B-lymphocyte stimulator
 - iv. Small molecule inhibitors of Janus kinase (JAK) enzymes
 - v. Phosphodiesterase 4 inhibitors
 - vi. Inhibitors of complement components
 - vii. Historical agents such as gold compounds, penicillamine, and minocycline
 - d. Urate lowering therapy
 - i. Xanthine oxidase inhibitors
 - ii. Uricosuric
 - iii. Uricase agents
 - e. Bone disorder medications
 - i. Bisphosphonates
 - ii. Anabolic agents
 - iii. RANKL inhibition

- iv. Sclerostin monoclonal antibody
- v. Hormonal therapy
- vi. Calcium and Vitamin D
- f. Vasodilators
 - i. Calcium channel blockers
 - ii. Topical nitrates
 - iii. Prostacyclin analogs
 - iv. Endothelin receptor antagonists
 - v. Phosphodiesterase 5 inhibitors
 - vi. Guanylate cyclase agonist
- g. Antibiotic therapy for septic joints
- h. Opioid and non-opioid analgesics
- i. Colchicine
- j. Agents used for pain modulation: anti-depressants, anti-convulsants, gapentinoids, muscle relaxants
- k. Cholinergics and non-pharmacologic agents used for the treatment of sicca symptoms
- I. Vaccines
- m. Intravenous immunoglobulin (IVIG)
- n. Plasma exchange
- o. Rehabilitation and disability Multidisciplinary approaches to rehabilitation and pain control: appropriate use of and referral/prescription to rehabilitation specialists and pain clinics
- p. Methods of rehabilitation: for each method, principles, mechanism of action, indications, precautions and contraindications, potential side effects, and costs
 - i. Exercise
 - ii. Rest and splinting
 - iii. Thermal Modalities
 - (1) Ultrasound
 - (2) Phonophoresis
 - (3) Spa therapy
 - (4) Icing
- q. Adaptive equipment and assistive devices
- r. Footwear and orthotics
- 2. Surgical and perioperative management
 - a. For each procedure, the fellow should demonstrate a working knowledge of indications, preoperative evaluation and medication adjustments, contraindications, complications, postoperative management, and expected outcome.
 - i. Bone biopsy
 - ii. Arthroscopy
 - iii. Synovectomy of tendons and joints
 - iv. Entrapment neuropathy release
 - v. Osteotomies: hip, knee
 - vi. Arthrodesis
 - vii. Spine surgery: radiculopathy, stenosis, and instability
 - viii. Reconstructive surgery of hand and foot
 - ix. Total joint replacement
 - x. Specific surgical management problems:
 - (1) Patient with rheumatoid arthritis
 - (2) Infected joint: arthroscopy vs. arthrotomy

- (3) Infected prosthetic joint
- (4) Patient with ankylosing spondylitis
- (5) Pediatric patient with rheumatic disease
- (6) Prevention and treatment of deep venous thrombosis
- (7) Peri-operative anti-rheumatic medication management
- 3. Complementary and alternative medical practices, including but not limited to: diet, nutritional supplements, acupuncture, chiropractic

DIAGNOSTIC TESTING

- A. Laboratory tests: rationale, methods for performing, and utility/limitations of specific laboratory tests including but limited to:
 - 1. Erythrocyte sedimentation rate, C-reactive protein, and other acute phase reactants (*ferritin, haptoglobin, ceruloplasmin, complement*)
 - 2. Rheumatoid factors, cryoglobulins, and circulating immune complexes (C1q)
 - 3. Anti-cyclic citrullinated peptide antibodies
 - Antibodies against nuclear antigens: ANA, anti-dsDNA, anti-Smith, anti-SSA, anti-SSB, anti-U1 RNP, anti-centromere, anti-histone, anti-ribosomal P, anti-topoisomerase 1, anti-U3 RNP, anti-RNA Polymerase III
 - 5. Lupus Erythematosus (LE) cell preparation
 - Myositis-specific autoantibodies (anti-Jo-1 and other anti-synthetases, anti-Mi-2, anti-SRP, anti-HMG CoA reductase [200/100], anti-TIF1-gamma [p155/140], anti-MJ [NXP-2], anti-CADM-140 [MDA-5], anti-SAE) and myositis-associated (anti-Ro, anti-U1RNP, anti-Ku, anti-PM-ScI) antibodies
 - 7. Other disease-associated auto-antibodies: anti-mitochondrial, anti-smooth muscle, anti-neuronal
 - 8. Anti-neutrophil cytoplasmic antibodies (anti-proteinase 3, anti-myeloperoxidase)
 - 9. Anti-phospholipid antibodies including RPR, lupus anticoagulant, anti-cardiolipin, anti-beta-2glycoprotein I and antiphosphatidylserine
 - 10. Antibodies to formed blood elements including direct and indirect Coombs testing, anti-platelet antibodies, anti-granulocyte antibodies
 - 11. Assays for complement activity (CH50) and components of the complement cascade
 - 12. Serum immunoglobulin levels, serum protein electrophoresis and immunofixation electrophoresis
 - 13. HLA typing (B27, B51, B5801)
 - 14. ASO and other streptococcal antibody tests
 - 15. Appropriate testing for Lyme disease, HIV, Hepatitis B, Hepatitis C, parvovirus, N. gonorrhea, chikungunya and other infectious agents
 - 16. Appropriate screening for hepatitis B, hepatitis C, tuberculosis
 - 17. Serum and urine measurements for uric acid
 - 18. Iron studies including total iron binding capacity, ferritin
 - 19. Flow cytometry studies for analysis of lymphocyte subsets and function
 - 20. Specific genetic testing
- B. Diagnostic imaging techniques: basic underlying principles and technical considerations in the use of plain radiographs, computed tomography, magnetic resonance imaging, ultrasonography and radionuclide scanning of bones, joints, periarticular and vascular structures
- C. Synovial fluid analysis: cell count and differential, Gram stain and bacterial culture, crystal identification, viscosity, and other special stains/analyses (AFB, fungal culture)
- D. Laboratory test-performance characteristics: principles of sensitivity, specificity, predictive value, and likelihood ratios

RESEARCH PRINCIPLES

- A. Basic Science Research: Fellows should demonstrate a basic knowledge of the principles of basic science research and the process of scientific experimentation and hypothesis testing including:
 - 1. Generating an experimental question and hypothesis

- 2. Experimental design
 - a. Designation of experimental group
 - b. Designation and selection of appropriate control group
 - c. Replication of results to assure reliability and validity
- 3. Laboratory techniques commonly used in research related to rheumatologic diseases basic understanding of methods
 - a. Clinical: ELISA, RIA, nephelometry, protein electrophoresis, multiplex bead-based immunoassays
 - b. Cellular: cell lines, lymphocyte proliferation, flow cytometry, fluorescence activated cell sorting (FACS), confocal microscopy
 - c. Immunohistochemistry and immunofluorescence of tissues.
 - d. Molecular: Western blot analysis, polymerase chain reaction; gene sequencing; genomics techniques (GWAS, SNPs, microarray techniques), proteomics techniques
 - e. Hybridoma and monoclonal antibody production
 - f. Mouse models: transgenic, knock-out/knock-in, chimeras
- 4. Statistical methods and reporting
 - a. Statistical tests for analysis of variables
 - b. Statistical significance and sample size
- B. Clinical Research: Fellows should understand the principles of research involving patients in order to answer clinically relevant questions, recognizing the limitations and biases of different study designs
 - 1. Generating an experimental question and hypothesis
 - 2. Research study design distinguish the critical components of clinical studies
 - a. Clinical trial design
 - i. Phase I clinical trials
 - ii. Phase IIa and IIb clinical trials
 - iii. Phase III clinical trials
 - iv. Randomized, double-masked, placebo-controlled trial
 - v. Cross-over trial designs
 - vi. Randomized discontinuation trial
 - vii. Open-label extensions
 - b. Observational study designs
 - c. Other study design
 - i. Meta-analysis
 - ii. Systematic Review
 - 3. Inclusion and exclusion criteria
 - 4. Concept of equipoise and its impact on study design
 - 5. Statistical methods and reporting
 - a. Sensitivity and specificity calculations
 - b. Odds ratios, hazards ratio, relative risk, number needed to treat, number needed to harm
 - c. Statistical significance, sample size, and power calculations
 - d. Student t-test, Chi-squared test, logistic regression, 95% confidence intervals
- C. Epidemiological and health services research: Fellows should recognize how research focused on population level measures, or on implementation and delivery of interventions is carried out at the local and global level
 - 1. Epidemiology study design
 - a. Types: Retrospective, case series, case-control, cohort, cross-sectional
 - b. Analysis: incidence, prevalence, correlation, predictive variables
 - 2. Outcomes measures
 - a. Patient reported outcomes (e.g. SF36, WOMAC, global assessments)
 - b. Disease activity indices (e.g. DAS, RAPID3, CDAI, SLEDAI, BASDAI, PASI, BVAS and others)
 - c. Composite indices (e.g. BILAG, SRI, BICLA, ACR Composite)
 - 3. Quality improvement science

- a. Plan-Do-Study-Act (PDSA) cycle
- b. Team leadership skills
- 4. Comparative effectiveness research
- D. Research Ethics: Fellows should know and practice the guiding principles of ethical research with a focus on the core principles of beneficence and non-malfeasance
 - 1. Guiding principles
 - a. Nuremberg code
 - b. Declaration of Helsinki
 - c. Belmont Report
 - 2. Independent review
 - a. Institutional Review Boards (IRB)
 - b. Data safety monitoring boards
 - 3. Informed consent
 - 4. Right to withdraw
 - 5. Data management
 - a. Confidentiality
 - b. Documentation
 - 6. Data security
- E. Critical literature review
 - 1. Evidence based medicine principles
 - 2. Critical appraisal of the literature

TELEHEALTH PRINCIPLES

- A. Fellows should demonstrate a basic knowledge of the principles of telehealth including:
 - 1. Types of Telehealth Encounters, as Categorized by:
 - a. Timing
 - i. Synchronous
 - ii. Asynchronous
 - b. Personnel Involved
 - i. eConsult
 - ii. Direct patient-to-provider virtual visits
 - iii. Patient to provider via mediator, where the patient is onsite with an axillary provider who may perform physical exam maneuvers and/or assist the patient with working telemedicine equipment
 - c. Method
 - i. Telephone visit
 - ii. Video visit
 - iii. Medical record review
 - Equipment Used in Virtual Medicine
 - a. Videoconferencing equipment (i.e. telephone, camera, etc.)
 - b. HIPAA Compliant Videoconferencing platforms (i.e. Zoom, Doximity, etc.)
 - c. Telemedicine peripherals (i.e. remote stethoscopes, otoscopes, ultrasound, etc.)
 - 3. Legal Regulations

2.

- a. Local, state, and federal licensure laws for telehealth
- b. Components of patients' informed consent for virtual encounters
 - i. Risks including breech of patient privacy, potential short-comings of virtual encounters, etc.
 - ii. Benefits including improved access to care, convenience, etc.

II. PATIENT CARE

The ability to provide quality patient care is the ultimate goal of clinical training in rheumatology. The fellowship program must require its trainees to attain competence in patient care to the level expected for independent practice, as defined by the Rheumatology Entrustable Professional Activities (EPA's) (Appendix B). Programs must define the specific knowledge, skills, behaviors, and attitudes required, as well as provide educational experiences as needed in order for their trainees to demonstrate quality patient care.

DEFINITION

Patient Care that is compassionate, appropriate, and effective for the treatment of disease and the promotion of health.

ESSENTIAL COMPONENTS

The essence of being a rheumatologist is the ability to use information derived about a patient (history, physical examination, laboratory and imaging studies) along with medical knowledge to orderly synthesize a differential diagnosis, plan of further evaluation and comprehensive management for the patient being evaluated for rheumatic disease or rheumatic disease manifestations. The rheumatologist should provide consultation when requested, in support of the primary care relationship, for patients with rheumatic symptoms and signs and appropriately integrate recommendations from other health care providers into the evaluation and management plan.

This may broadly be categorized under four components:

COMPONENT 1 - INFORMATION GATHERING

The fellow should be able to:

- 1. Obtain an accurate and comprehensive but relevant clinical history, including review of all available records.
- 2. Perform a thorough and relevant review of systems, and assess functional status of patients with rheumatic disease symptoms.
- 3. Perform and interpret a comprehensive, accurate physical examination, using common and advanced techniques, where applicable.
- 4. Perform and interpret the examination of all axial and peripheral joints, peri-articular structures, peripheral nerves and muscles.
- 5. Identify extra-articular findings that are associated with specific rheumatic diseases.
- 6. Recognize the indications for and costs of ordering laboratory tests and procedures to establish a diagnosis of rheumatic disease
- 7. Recognize the indications for and costs of different therapies used in the management of rheumatic diseases.
- 8. Recognize the indications for and demonstrate competence in arthrocentesis, joint and soft tissue injections. The fellow should be able to distinguish the anatomy, precautions (including OSHA requirements) and potential sequelae of arthrocentesis and demonstrate competency in obtaining synovial fluid from diarthrodial joints, bursae and tenosynovial structures after obtaining informed consent from the patient or caregiver.
- 9. Perform synovial fluid analysis including the examination and interpretation of synovial fluid under conventional and polarized light microscopy from patients with a variety of rheumatic diseases.

- 10. Obtain and interpret appropriate tests, including laboratory tests, imaging studies, and other indicated testing to evaluate patients presenting with known or possible rheumatic disease:
 - a. Radiographs of normal and diseased joints, bones, peri-articular structures and prosthetic joints
 - b. Bone densitometry
 - c. Arthrography, ultrasonography, computed tomography, magnetic resonance imaging of joints, bones, peri-articular structures and muscle
 - d. Radionuclide scans of bones and joints
 - e. Arteriograms (conventional, CT and MR) for patients with suspected or confirmed vasculitis
 - f. Computed tomography of lungs and paranasal sinuses
 - g. Magnetic resonance imaging of the central nervous system (brain and spinal cord)
 - h. Electromyograms and nerve conduction studies
 - i. Biopsy specimens including histochemistry and immunofluorescence of tissues relevant to the diagnosis of rheumatic diseases: skin, synovium, muscle, nerve, bone, minor salivary gland, artery, kidney and lung
 - j. Specific laboratory tests : See Medical Knowledge, Clinical Sciences, Diagnostic Testing A (*vide supra*)
 - k. Arthroscopy
 - I. Schirmer's and tests of corneal integrity; parotid scans and salivary flow studies

COMPONENT 2 - SYNTHESIS OF TREATMENT PLAN

Informed medical decision-making based on current scientific information and clinical judgment that also accounts for patient preferences and circumstances.

The fellow should be able to:

- 1. Construct a differential diagnosis in patients presenting with signs and symptoms related to rheumatologic diseases and to outline further testing necessary to establish the correct diagnosis
- 2. Construct and implement an appropriate treatment plan for the care of a patient with a rheumatologic problem integrating the prescribing of medications (oral, injectable or infused), counseling and psychosocial aspects, rehabilitative medicine, and, when necessary, surgical or other consultation. The fellow should be able to explain the rationale as well as the risks and benefits for the treatment plan
- Formulate and implement a management plan for patients with rheumatic emergencies (including organ or life threatening conditions), with a need for emergent, urgent or changes in level or goals of care
- 4. Recognize disease-related exacerbations and formulate and implement a management plan
- 5. Refer to, or consult with other health care providers for the co-management of patients with rheumatic disease
- 6. Identify opportunities for referral to clinical registries and trials

COMPONENT 3 - IMPLEMENTATION OF TREATMENT

A. Prescribing medications and rehabilitation The fellows should be able to:

Demonstrate a working knowledge of clinical pharmacology including the dosing, pharmacokinetics, metabolism, mechanisms of action, side effects, drug interactions, compliance issues, costs, and use in specific patient populations, such as chronic kidney disease and including fertile, lactating, and pregnant women and fertile men as well as across the age spectrum.

- 1. Nonsteroidal anti-inflammatory drugs and adequate gastroprotection
- 2. Glucocorticoids: topical, intra-articular, systemic
- 3. Systemic anti-rheumatic drugs
 - a. DMARDs, small molecules: anti-malarials, sulfasalazine, methotrexate, leflunomide, azathioprine, cyclophosphamide, mycophenolate mofetil, calcineurin inhibitors, JAK kinase inhibitors, phosphodiesterase inhibitors
 - b. Biologic agents: interleukin inhibitors (1, 6, 12, 17, 23), tumor necrosis factor inhibitors, T cell co-stimulatory inhibitors, anti-B cell therapy
 - c. Historical agents such as gold compounds
- 4. Urate lowering therapy:
 - a. Xanthine oxidase inhibitors: allopurinol, febuxostat
 - b. Uricosuric: probenecid
 - c. Uricase agents: pegylated uricase, rasburicase
- 5. Bone disorder medications
 - a. Bisphosphonates: alendronate, risedronate, ibandronate, zoledronic acid
 - b. Anabolic agents: teriparatide
 - c. RANKL inhibition: denosumab
 - d. Hormonal therapy: estrogen, selective estrogen receptor modulators, calcitonin
 - e. Calcium and Vitamin D
- 6. Vasodilators
 - a. Calcium channel blockers
 - b. Topical nitrates
 - c. Prostacyclin analogs
 - d. Endothelin receptor antagonists
 - e. Phosphodiesterase inhibitors
 - f. Guanylate cyclase agonist
- 7. Antibiotic therapy for septic joints
- 8. Opioid and non-opioid analgesics
- 9. Colchicine
- 10. Agents used for pain modulation: anti-depressants, anti-convulsants, pregabalin, muscle relaxants
- 11. Anti-cholinergics and non-pharmacologic agents used for the treatment of sicca symptoms
- 12. Vaccines
- 13. Intravenous immunoglobulin (IVIg)
- 14. Plasma exchange
- B. Pain assessment and pain management

The fellow should be able to utilize:

- 1. Methods of pain assessment including visual analog scale scores, pain questionnaires
- 2. Non-pharmacological modalities of pain management including exercise, cognitive behavioral therapy
- 3. Pharmacological therapy including:
 - a. Immunosuppressive and anti-inflammatory management of underlying rheumatic disorder.
 - b. Analgesic agents including acetaminophen, nonsteroidal anti-inflammatory agents and narcotic analgesics.
 - c. Antidepressants
- 4. Means to identify physical impairment; relate the impairment to the observed functional deficits; prescribe appropriate rehabilitation (physical therapy, occupational therapy) to achieve goals to improve the defined impairment.

C. Surgical management

The fellow should be able to:

- 1. Distinguish indications for surgical and orthopedic consultation in acute and chronic rheumatic diseases.
- 2. Perform peri-operative management of the surgical patient:
 - a. Peri-operative evaluation, appropriate referral and medication adjustments.
 - b. Rehabilitation of the patient with rheumatic disease after a surgical or orthopedic procedure, as well as aspects of post-operative medical management pertaining to the rheumatologic condition.
- D. Non-pharmacologic management
 - The fellow should be able to:
 - 1. Describe complementary and unconventional medical practices: diet, nutritional supplements, antimicrobials, acupuncture, topical therapeutic agents, homeopathic remedies, venoms, and others.
 - 2. Perform patient education and counseling
- E. Preventive medicine and proactive care

The fellow should be able to:

- 1. Appropriately assess and manage of bone health in a patient starting or taking glucocorticoid therapy
- 2. Counsel for risk factor modification for patients at risk for fracture
- 3. Recognize the importance of lipid panel monitoring in patients with rheumatic disease
- 4. Appropriately implement prophylaxis against pneumocystis pneumonia
- 5. Counsel for tobacco cessation
- 6. Appropriately screen for risk for reactivation of infectious diseases (viral hepatitis, tuberculosis) in patients beginning disease modifying, small molecules or biologic therapy
- 7. Counsel for appropriate dental evaluation and management
- 8. Counsel for appropriate vaccination administration

COMPONENT 4 - REASSESSMENT AND PATIENT FOLLOW UP

The fellow should be able to:

- 1. Reassess the patient over time, including recognition of treatment related adverse events, and alter the treatment plan accordingly.
- 2. Utilize the validated instruments in the assessment of pain, disease activity, function, and quality of life over time to monitor and adjust therapy
- 3. Address comorbid illness in patients with rheumatic diseases and incorporate these considerations into the care plan
- 4. Enumerate disease- and treatment-related complications that may lead to long term morbidity, considering implications of comorbid diseases and effects of aging

III. PRACTICE-BASED LEARNING AND IMPROVEMENT

The practice of rheumatology entails the assessment and treatment of patients with clinical disorders that are often complex with regard to the different organ systems involved, variations in musculoskeletal and immune system biology, and impact upon patient lifestyle and livelihood. The rapid advances in understanding and the complexity of both disease pathogenesis and treatment of the rheumatic diseases demand that the rheumatologist continually evaluate and improve the quality of his/her care in the context of his/her own clinical practice. The development of skills in self-directed, reflective learning and practice improvement will facilitate the delivery of state-of-the-art, evidence-based patient care that maximizes the likelihood for successful clinical outcomes.

DEFINITION

Practice-based learning and improvement involves the evaluation of care provided to both individual patients as well as to groups of patients in a given practice, the appraisal and assimilation of scientific evidence relevant to clinical problems encountered, evaluations of the care provided in the context of this evidence, and effecting improvements in patient care based upon these evaluations.

ESSENTIAL COMPONENTS

In addition to structured learning of the basic components of medical knowledge and patient care, the rheumatologist must evaluate his/her knowledge base and care delivery on an ongoing basis with the goal of continually improving that care. This process includes the following components:

- A. Independent Learning The fellow should be able to:
 - 1. Learn and improve at the point of care to enhance future clinical interactions
 - 2. Seek resources to enhance future clinical interactions.
 - 3. Recognize, and implement ways to improve his/her role in the effective management of a practice.
 - 4. Incorporate technology to manage information (HIPAA compliant), support patient care decisions using evidence-based medicine and enhance both patient and physician education
- B. Self-evaluation of performance The fellow should be able to:
 - 1. Monitor practice with goal for improvement
 - 2. Honestly reflect on knowledge, skills or attitude gaps to guide ongoing learning, using internal and external sources
 - 3. Actively seek, reflect on, and develop plans for practice improvement based on feedback from all members of the health care team including faculty, peers, students, health professionals, patients and patient advocates.
- C. Incorporation of feedback into improvement of clinical activity The fellow should be able to:
 - 1. Demonstrate that s/he learns from errors through actions taken to improve the system or processes of care.
 - 2. Display the ability to change practice based on an audit of a panel of patients using standardized, disease specific, and evidence based criteria.
 - 3. Independently construct and pursue answers to clinical questions, and perform self-reflection to incorporate learning for future clinical encounters.
 - 4. Demonstrate the ability to respond to meet situational needs, and customize management based on clinical evidence for individualized patient care.
- D. Incorporation of feedback into improvement of clinical activity The fellow should be able to:
 - 1. Demonstrate that s/he learns from errors through actions taken to improve the system or processes of care.

- 2. Display the ability to change practice based on an audit of a panel of patients using standardized, disease specific, and evidence based criteria.
- 3. Independently construct and pursue answers to clinical questions, and perform self-reflection to incorporate learning for future clinical encounters.
- 4. Demonstrate the ability to respond to meet situational needs, and customize management based on clinical evidence for individualized patient care.

IV. SYSTEMS-BASED PRACTICE

The increasing complexity and diversity of health care delivery systems presents both challenges and opportunities for the practice of rheumatology. Knowledge of the nature and variety of the external and internal systems that can impact clinical practice and the effective utilization of that knowledge to positively impact patient care is an essential skill. It is important for trainees to both recognize how their own practices intersect with others, and to work in teams to improve health care delivery.

The knowledge base of systems-based practice comprises the advantages and disadvantages of different health care systems that impact patients with rheumatic diseases. Some of these include the academic system in which rheumatology fellows are training, the various private and public health care delivery systems, the governmental agencies and programs that regulate these systems, the volunteer, private and governmental agencies that are available to educate and assist patients, the challenges faced by disabled patients negotiating these systems and the social and economic burden of chronic rheumatic diseases. The goal of the systems-based practice curriculum is to enhance the ability of rheumatology trainees to positively influence patient care by effectively utilizing these internal and external resources, to serve as effective advocates for their patients, and to provide cost-effective patient care. In some cases this may also mean identifying and organizing changes in the local systems' problems that can improve patient care.

DEFINITION

Systems-based practice reflects an understanding of and responsiveness to the larger context and system of health care, as well as the ability to call effectively on other resources in the system to provide optimal health care.

ESSENTIAL COMPONENTS

A. Partners in health care delivery: the various providers and resources available to deliver optimal care.

This partnership starts with coordinating both a multidisciplinary and interprofessional approach to patient-centered care. The principal partners in delivering health care to patients with rheumatic diseases include providers such as administrative and nursing staff, referring and consulting physicians, nurse practitioners, physician assistants and other health professionals participating in the local health care system. Partners also include outside volunteer agencies, both locally and nationally, such as the American College of Rheumatology, Association of Rheumatology Health Professionals, the Rheumatology Research Foundation, the Arthritis Foundation, the disease-specific foundations (including but not limited to Lupus, Scleroderma, Ankylosing Spondylitis, Vasculitis), the National Institute of Health (NIH) and its component institutes and pharmaceutical companies that have specific patient-related initiatives. Other agencies that have impact on the practice of rheumatology include the American Medical Association (AMA), the Food and Drug Administration (FDA) and the Center for Medicare and Medicaid Services (CMS).

Working within interprofessional and interdisciplinary teams, rheumatologists should work to promote patient safety. It is also important to identify risks for and strategies to prevent medical errors and to

address them appropriately if they occur.

B. Systems thinking: a concept of "systems thinking" in health care delivery

This includes an appreciation for the spectrum of practice models for health care delivery (academic/public/private/Veterans Affairs) including the fundamentals of office and personnel management, practice management strategies, managed care, health insurance, appropriate coding and reimbursement policies.

It also comprises an ongoing analysis of the limitations and opportunities within the local health care system, in both the inpatient and outpatient settings, and its impact on the health care delivery to patients with rheumatic diseases. In particular, efforts should be made to identify potentially correctable systems' weaknesses and medical errors due to systems' failures and to develop strategies to rectify the problems (i.e. quality improvement projects).

Systems thinking includes implementing strategies to coordinate care and transition patients safely and efficiently across multiple delivery systems, including ambulatory, sub-acute, acute, rehabilitation and skilled nursing facilities.

C. Advocacy for the patient: the importance, opportunities and limits of patient advocacy

This advocacy includes assisting patients with applications for medical disability determinations, completing preauthorization documents for the use of certain medications and appealing to insurance companies with respect to denial of certain treatments, benefits and claims.

It is also important to recognize opportunities to address disparities in disease and in health care delivery impacting patient care, including socio-economic factors, health care literacy, medical disability and health care insurance coverage.

Activities may include broader advocacy for populations on a local, state or national level.

D. Cost-effective health care: the principles of cost allocation and resource management within the external (state, national) and local systems

The delivery of cost-effective health care includes realizing how the cost and availability of certain diagnostic tests, drugs and other therapies impact patient care. The utilization of evidence-based cost-conscious best practice strategies for the diagnosis and treatment of patients with rheumatic diseases is paramount.

V. INTERPERSONAL AND COMMUNICATION SKILLS

Interpersonal and communication skills are essential for the formation of a desirable and effective physicianpatient relationship. The complexity of most of the rheumatic diseases, as well as the increasingly complicated treatment regimens, require a working partnership between patient and physician, and often between both physician and the patient's family or caregiver(s), as well as physician and members of an interprofessional team of providers. In addition to improved patient satisfaction, confidence and understanding, such working partnerships promote medical compliance. Effective physician collegial relationships are also dependent upon these skills.

DEFINITION

Interpersonal and communication skills that result in the effective exchange of information and collaboration with patients, their families, and other health professionals.

ESSENTIAL COMPONENTS

- A. Gathering information Reliable and effective communication depends upon the availability of accurate and complete information obtained from patients, their families, other health professionals, and the complete medical record. This requires the use of effective listening and communication skills.
- B. Recognizing and incorporating the patient's perspective Such understanding impacts the ability of the physician to appreciate the functional impact of disease and the desire and ability of the patient to be an active partner in decision-making and treatment efforts. Evaluation and management plans should demonstrate sensitivity to, and integrate differences in patient characteristics.
- C. Providing information

Communication regarding disease manifestations, diagnosis and treatment is only effective if the recipient has gained appropriate understanding of the information at the end of the exchange. Effective explanation and documentation therefore require that the physician communicate in a manner that is clear and is adjusted to the specific context, situation, and/or audience.

D. Trust

Establishment of trust with the patient, the patient's family or caregiver(s), and other health professionals is paramount.

VI. PROFESSIONALISM

Professionalism is one of the foundations of the practice of medicine. By virtue of their prior medical school education and internal medicine training, rheumatology fellows have typically already attained a substantial level of professionalism, which can be further enriched during the fellowship training period. The complexity of rheumatic diseases and their management requires effective interactions between rheumatology trainees and referring providers, subspecialty consultants, other health care providers, hospital administrators and health insurance representatives in providing care for their patients. Trainees in many programs interact with patients from a wide range of cultural and socioeconomic backgrounds. In addition, fellows must learn to recognize and manage potential conflicts of interest with professional activities as well as with pharmaceutical companies (i.e. clinical research trials, pharmaceutical company interactions, grant review processes). A high level of professionalism is thus essential to maintain the balance required be an effective rheumatologist.

DEFINITION

Professionalism is manifested through a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to patients of diverse backgrounds.

ESSENTIAL COMPONENTS

A. Primacy of patient interest

Placing the interest of the patient before all other external interests is the most fundamental aspect of the medical profession and forms part of the unwritten contract in the patient-physician relationship. This primacy also implies patient autonomy in the determination of treatment. As a demonstration of patient advocacy, the fellow needs to respond to each patient's unique characteristics and needs. This includes but is not limited to:

- 1. Demonstrating empathy and compassion to all patients,
- 2. Addressing disparities in health care that may impact patient care, and
- 3. Taking responsibility for situations where public health supersedes individual privacy (e.g. reportable infectious diseases).
- B. Physician responsibility and accountability

The practice of medicine incurs responsibility and accountability to patients, colleagues, society, and self. The physician must maintain professional and respectful interactions with patients, caregivers, and members of the interprofessional team (e.g., peers, consultants, nursing, ancillary professionals, and support personnel).

- 1. To demonstrate commitment to providing safe patient care, the physician must recognize, respond to, and report either the impairment in colleagues, or the provision of substandard care, via a peer review process.
- 2. To demonstrate the professional attribute of accessibility, the physician accepts responsibility and follows through on tasks, including but not limited to completion of clinical, administrative, curricular and research-related tasks.
- 3. To demonstrate the professional attribute of personal accountability, the physician should contribute to the fiscally sound practice of medicine.
- 4. Physicians should responsibly use technology and social media.
- 5. To manage conflicts of interest the physician must maintain ethical relationships with patients, colleagues, members of the interprofessional team, office staff and industry.
- C. Humanistic qualities and altruism

Physicians should treat patients with dignity, civility and respect, regardless of race, culture, gender, sexual orientation, socioeconomic status, literacy, and religious beliefs.

1. To demonstrate compassion and respect to patients and their caregivers, physicians should endeavor to support patients' needs (physical, psychological, social, and spiritual)

D. Ethical behavior

The physician must exhibit integrity and ethical behavior in professional conduct.

- 1. This includes, but is not limited to, accepting personal errors and honestly acknowledging them, maintaining patient confidentiality, upholding ethical expectations of clinical, scholarly and research activities, as well as maintenance of credentialing requirements.
- 2. The physician must address personal, psychological, and physical limitations that may affect professional performance.
- 3. Integrity must pervade all of the components of professionalism.

APPENDICES

APPENDIX A. RHEUMATOLOGY MILESTONES 2.0



Rheumatology Milestones

The Accreditation Council for Graduate Medical Education



Second Revision: August 2020 First Revision: October 2014

Rheumatology Milestones

The Milestones are designed only for use in evaluation of fellows in the context of their participation in ACGMEaccredited residency or fellowship programs. The Milestones provide a framework for the assessment of the development of the fellow in key dimensions of the elements of physician competence in a specialty or subspecialty. They neither represent the entirety of the dimensions of the six domains of physician competence, nor are they designed to be relevant in any other context.

Rheumatology Milestones Work Group

Michael Battistone, MD Marcy B. Bolster, MD Anisha Dua, MD, MPH Laura Edgar, CAE, EdD Karen Gouze, PhD Jason Kolfenbach, MD Jason Liebowitz, MD Bethany Marston, MD Kevin McKown, MD Kenneth O'Rourke, MD Karina Torralba, MD, MACM, RhMSUS, CCD Joanne Valeriano-Marcet, MD

The ACGME would like to thank the following organizations for their continued support in the development of the Milestones:

American Board of Internal Medicine American College of Rheumatology Review Committee for Internal Medicine

Understanding Milestone Levels and Reporting

This document presents the Milestones, which programs use in a semi-annual review of fellow performance, and then report to the ACGME. Milestones are knowledge, skills, attitudes, and other attributes for each of the ACGME Competencies organized in a developmental framework. The narrative descriptions are targets for resident/fellow performance throughout their educational program.

Milestones are arranged into levels. Tracking from Level 1 to Level 5 is synonymous with moving from novice to expert fellow in the specialty or subspecialty. For each reporting period, the Clinical Competency Committee will review the completed evaluations to select the milestone levels that best describe each learner's current performance, abilities, and attributes for each subcompetency.

These levels *do not* correspond with post-graduate year of education. Depending on previous experience, a junior fellow may achieve higher levels early in his/her educational program just as a senior fellow may be at a lower level later in his/her educational program. There is no predetermined timing for a resident to attain any particular level. Fellows may also regress in achievement of their milestones. This may happen for many reasons, such as over scoring in a previous review, a disjointed experience in a particular procedure, or a significant act by the fellow.

Selection of a level implies the fellow substantially demonstrates the milestones in that level, as well as those in lower levels (see the diagram on page vi).

Additional Notes

Level 4 is designed as a graduation *goal* but *does not* represent a graduation *requirement*. Making decisions about readiness for graduation and unsupervised practice is the purview of the program director. Furthermore, Milestones 2.0 include revisions and changes that preclude using Milestones as a sole assessment in high-stakes decisions (i.e., determination of eligibility for certification or credentialing). Level 5 is designed to represent an expert fellow whose achievements in a subcompetency are greater than the expectation. Milestones are primarily designed for formative, developmental purposes to support continuous quality improvement for individual learners, education programs, and the specialty. The ACGME and its partners will continue to evaluate and perform research on the Milestones to assess their impact and value.

Some milestone descriptions include statements about performing independently. These activities must occur in conformity to ACGME supervision guidelines as described in the Program Requirements, as well as to institutional and program policies. For example, a fellow who performs a procedure independently must, at a minimum, be supervised through oversight.

A Supplemental Guide is also available to provide the intent of each subcompetency, examples for each level, assessment methods or tools, and other available resources. The Supplemental Guide, like examples contained within the Milestones, is designed only to assist the program director and Clinical Competency Committee, and is not meant to demonstrate any required element or outcome.

Additional resources are available in the <u>Milestones</u> section of the ACGME website. Follow the links under "What We Do" at <u>www.acgme.org</u>.

The diagram below presents an example set of milestones for one sub-competency in the same format as the ACGME Report Worksheet. For each reporting period, a fellow's performance on the milestones for each subcompetency will be indicated by selecting the level of milestones that best describes that fellow's performance in relation to those milestones.

| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|---|--|--|---|--|
| Establishes personal and professional goals, identifying gap(s) between goals and current performance | Demonstrates receptiveness to feedback, analyzing and reflecting on factors contributing to gap(s) between goals and current performance | Seeks feedback episodically, and institutes behavioral change(s) when necessary | Seeks feedback consistently, and sustains behavioral change as necessary | Role models consistently seeking performance data with adaptability and humility, and coaches others on reflective practice |
| | Designs and implements a learning plan, with prompting | Independently creates and implements an individualized learning plan | Uses performance data to measure the effectiveness of the learning plan and when necessary, improves it | Facilitates the design and implementing learning plans for others |
| | | | | |
| Comments: | | | | |
| Selecting a response box in the middle of a level implies that milestones in that level and in lower levels have been substantially demonstrated. | | between level in lower level demonstrated | esponse box on the line i ils indicates that milestor s have been substantially d as well as some the higher level(s). | nes |

Practice-Based Learning and Improvement 2: Commitment to Reflective Practice and Personal Growth

©2020 Accreditation Council for Graduate Medical Education (ACGME)

All rights reserved except the copyright owners grant third parties the right to use the Rheumatology Milestones on a non-exclusive basis for educational purposes.

| Patient Care 1: Gathers an Essential and Accurate Patient History | | | | |
|---|--|---|---|---|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| Acquires a basic rheumatic history Reviews available medical records | Integrates a rheumatic history with a comprehensive medical history, including functional aspects Identifies relevant findings in the medical record | Acquires a tailored comprehensive rheumatic history, including historical subtleties and psychosocial aspects Independently requests additional information to supplement available medical records | Integrates the current patient history with the complete medical record, supplemental information, and disease activity measures | Identified as a role model in interpreting subtleties and resolving ambiguities in the patient history |
| | | | | |
| Comments: Not Yet Completed Level 1 | | | | |

| Patient Care 2: Physical Examination | | | | |
|---|---|---|--|---|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| Identifies the elements of a comprehensive physical examination | Performs all elements of a comprehensive physical examination | Performs a tailored comprehensive physical examination including advanced techniques, when applicable | Performs a tailored comprehensive physical examination that elicits subtle findings | Identified as a role model for performing and interpreting a comprehensive, accurate physical and musculoskeletal examination |
| Identifies the elements of a musculoskeletal examination | Performs all elements of a musculoskeletal examination | Performs a tailored comprehensive musculoskeletal examination including advanced techniques, when applicable | Performs a tailored comprehensive musculoskeletal examination that elicits subtle findings | |
| | | | | |
| Comments: Not Yet Completed Level 1 | | | | |

| Patient Care 3: Comprehensive Management Plan Development | | | | |
|--|---|--|--|---|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| With supervision, formulates a differential diagnosis for a patient | Independently formulates a broad differential diagnosis for typical disease presentations | Independently formulates a prioritized differential diagnosis for typical disease presentations | Independently formulates a prioritized differential diagnosis with consideration of typical and atypical disease presentations | Independently formulates a prioritized differential diagnosis with consideration of newly recognized and emerging conditions |
| Demonstrates an awareness of disease activity measures With supervision, develops a management plan | Identifies applicable disease activity measures Independently develops a management plan for a patient with common disease presentations | Incorporates and interprets the results of disease activity measure Independently recognizes disease acuity, and with supervision, develops a prioritized management plan | Independently develops and implements a prioritized management plan with consideration of acuity and complexity of disease presentation | Identified as an expert resource for management of a focused disease area |
| | | | | |
| Comments: Not Yet Completed Level 1 Not Yet Assessable Image: Second sec | | | | |

| Patient Care 4: Therapeutics, including Immunomodulatory Agents | | | | | |
|---|--|---|--|--|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 | |
| Identifies indications and adverse effects of medications used to treat patients with common rheumatic conditions | Prescribes and monitors medications used in patients with common rheumatic conditions | Prescribes, monitors, and assesses the response to pharmacotherapy used in the management of patients with common rheumatic conditions | Integrates best available evidence to prescribe, monitor, and assess the response to pharmacotherapy used in the management of patients with common and complex rheumatic conditions | Develops a clinical practice pathway for management of patients with rheumatic conditions | |
| | Evaluates for comorbidities that may alter therapeutic recommendations | Modifies treatment plans to address comorbidities, with supervision | Independently modifies treatment plans to address comorbidities | | |
| | | | | | |
| Comments: Not Yet Completed Level 1 Not Yet Assessable | | | | | |

| Patient Care 5: Procedures | | | | |
|--|--|--|---|---|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| Identifies indications for joint and soft tissue aspirations and injections, and discusses principles of informed consent | Performs common joint and soft tissue injections and aspirations with direct supervision, including independently discussing risks and benefits, obtaining informed consent, identifying anatomic landmarks, and demonstrating aseptic technique | Performs common joint and soft tissue aspirations and injections with indirect supervision | Independently performs common joint and soft tissue aspirations and injections | Independently performs complex joint and soft tissue aspirations or injections, including unusual sites, anatomic abnormalities, or incorporating imaging guidance |
| | Recognizes the role of musculoskeletal ultrasound in the diagnosis and treatment of patients with rheumatic conditions | Interprets the findings of musculoskeletal ultrasound for common conditions with supervision | Independently interprets the findings of musculoskeletal ultrasound for common conditions, and recognizes the role of ultrasound in non- musculoskeletal rheumatic conditions | Independently performs and interprets point-of- care diagnostic ultrasound and uses ultrasound to guide invasive procedures |
| Comments: | | | | |
| Comments. | | | Not Yet Co Not Yet As | ompleted Level 1 Impleted Level 1 ssessable Impleted Level 1 |

| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|--|--|--|---|--|
| Respectfully receives a consultation request | Clearly and concisely responds to a consultation request | Verifies understanding of recommendations with the primary team when providing consultation | Integrates recommendations from different members of the health care team and effectively conveys consultative assessment and rationale to all health care team members | Identified as a role model for the provision of consultative care across the spectrum of disease complexity and acuity |
| With supervision, recognizes disease acuity | Independently recognizes disease acuity | Recognizes disease acuity and prioritizes management steps | Mobilizes resources to provide care in high- acuity situations | |
| | | | | |
| Comments: Not Yet Completed Level 1 Not Yet Assessable | | | | |

| Medical Knowledge 1: Possesses Clinical Knowledge | | | | |
|--|---|--|--|---|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| Identifies key features of common rheumatic conditions | Demonstrates broad knowledge of common rheumatic conditions | Demonstrates knowledge of less common rheumatic conditions as well as common rheumatic conditions associated with higher complexity | Integrates knowledge of the pathogenesis, epidemiology, clinical expression, treatments, and prognosis of a broad range of rheumatic conditions | Identified as a subject matter expert in basic and/or clinical science of |
| Demonstrates basic knowledge of anatomy, physiology, and other basic sciences | Demonstrates basic knowledge of anatomy, genetics, immunology, metabolism, and other basic sciences pertaining to rheumatic conditions | Demonstrates in-depth knowledge of anatomy, genetics, immunology, metabolism, and other basic sciences pertaining to rheumatic conditions | Integrates knowledge of anatomy, genetics, immunology, metabolism, and other basic sciences pertaining to a broad range of rheumatic conditions | rheumatic conditions |
| | | | | |
| Comments: Not Yet Completed Level 1 | | | | |

| Medical Knowledge 2: Knowledge of Diagnostic Testing | | | | | |
|---|---|--|--|--|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 | |
| Explains the rationale, risks, and benefits for common diagnostic testing in patients being evaluated for rheumatic conditions | Integrates value and test characteristics into diagnostic strategies in patients with uncomplicated rheumatic conditions | Integrates value and test characteristics into diagnostic strategies in patients with complex rheumatic conditions | Integrates and reconciles information, including non-specific and/or conflicting diagnostic test results to form a cohesive evaluation | Identified as an expert in testing strategies and in the selection and interpretation of complex, new, or emerging tests | |
| | | | | | |
| Comments: Not Yet Completed Level 1 | | | | | |
| | | | Not Yet As | ssessable | |

| Medical Knowledge 3: Scholarly Activity | | | | | |
|---|--|--|---|---|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 | |
| Identifies areas worthy of scholarly investigation, with supervision | Designs a scholarly activity with a mentor(s) | Engages in scholarly work, incorporates feedback, and participates in critical appraisal and analysis of project data | Produces scholarly work suitable for dissemination as an abstract or presentation | Dissemination of independent scholarly work that has generated new medical knowledge, educational programs, or process improvement | |
| | | | | | |
| Comments: | | | Not Yet C Not Yet A | ompleted Level 1 | |

| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|---|---|---|---|---|
| Demonstrates knowledge of common patient safety events | Identifies system factors that lead to patient safety events | Participates in analysis of patient safety events (simulated or actual) | Conducts analysis of patient safety events and offers error prevention strategies (simulated or actual) | Actively engages teams and processes to modify systems to prevent patient safety events |
| Demonstrates knowledge of how to report patient safety events | Reports patient safety events through institutional reporting systems (actual or simulated) | Participates in disclosure of patient safety events to patients and families (simulated or actual) | Discloses patient safety events to patients and families (simulated or actual) | Role models or mentors others in the disclosure of patient safety events |
| Demonstrates knowledge of basic quality improvement methodologies and metrics | Describes quality improvement initiatives relevant to rheumatology practice | Participates in quality improvement initiatives relevant to rheumatology practice | Demonstrates the skills required to identify, develop, implement, and analyze a quality improvement project | Creates, implements, and assesses quality improvement initiatives at the institutional or community level |
| | | | | |

| Demonstrates | Coordinates care of | | | |
|---|---|---|--|---|
| nowledge of care coordination | patients in routine clinical situations effectively using the roles of the interprofessional teams | Coordinates care of patients in complex clinical situations effectively using the roles of their interprofessional teams | Role models effective coordination of patient- centered care among different disciplines and specialties | Leads in the design and implementation of improvements to the care coordination process |
| dentifies key elements or safe and effective ransitions of care and and-offs | Performs safe and effective transitions of care/hand-offs in routine clinical situations | Performs safe and effective transitions of care/hand-offs in complex clinical situations | Role models and advocates for safe and effective transitions of care/hand-offs within and across health care delivery systems including outpatient settings | Improves quality of transitions of care within and across health care delivery systems to optimize patient outcomes |
| Demonstrates nowledge of population and community health needs and disparities | Identifies specific population and community health needs and inequities for their local population | Uses local resources effectively to meet the needs of a patient population and community | Participates in changing and adapting practice to provide for the needs of specific populations | Leads innovations and advocates for populations and communities with health care inequities |

©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Rheumatology Milestones on a non-exclusive basis for educational purposes

| Systems-Based Practice 3: Physician Role in Health Care Systems | | | | | |
|--|---|--|---|---|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 | |
| Identifies key components of the complex health care system (e.g., hospital, skilled nursing facility, finance, personnel, technology) | Describes how components of a complex health care system are interrelated, and how this impacts patient care | Discusses how individual practice affects the broader system (e.g., length of stay, readmission rates, clinical efficiency) | Manages various components of the complex health care system to provide efficient and effective patient care and transition of care | Advocates for or leads systems change that enhances high-value, efficient, and effective patient care and transition of care | |
| Recognizes the impact of cost and patient payment model on care decisions | Identify the principles of high-value care and delivers care with consideration of each patient's payment model | Engages with patients in shared decision making and incorporates principles of high-value care into management plans | Advocates for individual patient care needs to provide high-value care | Participates in health policy advocacy activities | |
| | Demonstrates use of information technology (e.g., electronic health record) needed for clinical practice | Demonstrates knowledge of current evaluation and management billing practices | Independently completes proper documentation and coding for a patient encounter | Educates others on proper documentation, billing, and coding practices | |
| | | | | | |
| Comments: | Comments: | | | | |

©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Rheumatology Milestones on a non-exclusive basis for educational purposes

| Practice-Based Learning and Improvement 1: Evidence-Based and Informed Practice | | | | |
|---|--|--|--|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| Formulates clinical questions and elicits patient preferences to inform care | Locates available evidence and incorporates patient preferences to inform patient care | Evaluates and applies best available evidence and incorporates patient preferences and values in order to provide care tailored to individual patients | Critically appraises and applies evidence, and recognizes gaps and conflicting evidence to guide care tailored to individual patients | Coaches others to critically appraise and apply evidence for complex patients; and/or participates in the development of guidelines |
| | | | | |
| Comments: | | | | |

| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|---|--|--|---|--|
| Establishes personal and professional goals, identifying gap(s) between goals and current performance | Demonstrates receptiveness to feedback, analyzing and reflecting on factors contributing to gap(s) between goals and current performance | Seeks feedback episodically, and institutes behavioral change(s) when necessary | Seeks feedback consistently, and sustains behavioral change as necessary | Role models consistently seeking performance data with adaptability and humility, and coaches others on reflective practice |
| | Designs and implements a learning plan, with prompting | Independently creates and implements an individualized learning plan | Uses data and feedback from multiple sources to measure the effectiveness of the learning plan and when necessary, improves it | Facilitates the design and the implementation of learning plans for others |
| | | | | |

| Professionalism 1: Professional Behavior | | | | |
|---|--|---|--|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
| Describes when and how to appropriately report professionalism lapses, including strategies for addressing common barriers | Identifies and describes triggers for professionalism lapses and takes responsibility for own professional behavior | Proactively recognizes situations that may trigger professionalism lapses | Demonstrates professional behavior in complex or stressful situations and intervenes to prevent lapses in self and others | Coaches others when behavior fails to meet professional expectations |
| | | | | |
| Comments: | | | | |

| Professionalism 2: Ethical Principles | | | | | | |
|--|--|--|--|---|--|--|
| Level 1 | Level | Level 3 | Level 4 | Level 5 | | |
| Demonstrates knowledge of basic ethical principles | Applies basic principles to resolve straightforward ethical situations | Analyzes complex situations using ethical principles and recognizes need to seek help in resolving complex ethical situations | Manages and resolves complex ethical dilemmas using available resources | Identifies and seeks to address system-level factors that induce or exacerbate ethical problems or impede their resolution | | |
| | | | | | | |
| Comments: | | | Not Yet C | ompleted Level 1 | | |

| Professionalism 3: Accountability/Conscientiousness | | | | | | |
|---|---|--|--|---|--|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 | | |
| Performs tasks and responsibilities, with prompting | Performs tasks and responsibilities in a timely manner with attention to detail in routine situations | Performs tasks and responsibilities in a timely manner with attention to detail in complex or stressful situations | Demonstrates leadership to ensure tasks and responsibilities are completed in a timely manner with attention to detail in complex or stressful situations | Creates strategies to enhance others' ability to efficiently complete tasks and responsibilities | | |
| Takes responsibility for failure to complete tasks and responsibilities | Recognizes situations that may impact own ability to complete tasks and responsibilities in a timely manner | Recognizes situations that may impact others' ability to complete tasks and responsibilities in a timely manner | Proactively implements strategies to ensure that the needs of patients, teams, and systems are met | | | |
| | | | | | | |
| Comments: Not Yet Completed Level 1 | | | | | | |

| Professionalism 4: Self-Awareness and Help-Seeking | | | | | | |
|---|---|--|--|---|--|--|
| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 | | |
| Recognizes status of own and others' well- being, with assistance | Independently recognizes status of own and others' well-being, and asks for help when needed | Recognizes the impact of own and others' well- being on the patient and team, with assistance | Independently recognizes the impact of own and others' well- being on the patient and team, and asks for help when needed | Leads initiatives to improve wellness at the program or institutional level | | |
| With assistance recognizes personal gaps in knowledge, skills, and attitudes | Independently recognizes limits in personal knowledge, skills, and attitudes | With assistance, develops a plan to improve personal knowledge, skills, and attitudes | Independently implements a plan to improve personal knowledge, skills, and attitudes | Coaches others when limitations in knowledge, skills, and attitudes do not meet professional expectations | | |
| | | | | | | |
| Comments: Not Yet Completed Level 1 | | | | | | |

| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 | |
|---|---|--|---|---|--|
| Uses language and nonverbal behavior to demonstrate respect and establish rapport | Establishes a therapeutic relationship with the patient in uncomplicated clinical encounters using active listening and clear language | Establishes a therapeutic relationship with the patient in challenging clinical encounters | Consistently establishes and maintains therapeutic relationships using shared decision making | Serves as a role model in establishing respectful, culturally sensitive | |
| Recognizes common barriers to effective communication (e.g., language, disability) while accurately communicating own role within the health care system | Recognizes complex barriers to effective communication (e.g., health literacy, cultural competency) | Adjusts communication strategies based on identified barriers, incorporating patient and caregiver expectations and goals of care | Uses self-reflection to proactively minimize communication barriers | therapeutic relationships while mitigating communication barriers | |
| Comments: | | | | | |

| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|--|---|--|---|--|
| Uses language that is respectful and values all members of the health care team | Communicates basic information effectively with all health care team members | Communicates highly complex information effectively with all health care team members | Optimizes flexible communication strategies using input from all team members to build consensus and resolve conflicts, as needed | Demonstrates leadership in promoting open and safe communication within and between teams |
| Accepts feedback from team members | Solicits feedback on performance as a member of the health care team | Provides feedback to peers and other learners on the team | Communicates detailed and effective feedback to any member of the health care team | Educates others in providing effective feedback |

| Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|---|---|--|--|---|
| Accurately records information in the patient record | Demonstrates organized diagnostic and therapeutic reasoning through notes in the patient record | Concisely reports diagnostic and therapeutic reasoning in the patient record | Communicates clearly, concisely, timely, and in an organized written form, including anticipatory guidance | |
| Safeguards patient personal health information in direct (e.g., telephone, in- person) and indirect (e.g., progress notes, text messages) communications | Accurate and timely documentation with appropriate use of documentation tools | Appropriately selects direct and indirect forms of communication based on context | Produces written or verbal communication (e.g., patient notes, email) that could serve as an example for others to follow | Participates in establishing communication tools or policies for the division, department, or institution |
| | | | | |

APPENDIX B. RHEUMATOLOGY ENTRUSTABLE PROFESSIONAL ACTIVITES



Empowering Rheumatology Professionals

Adult Rheumatology Entrustable Professional Activities (EPA)

Approved by the American College of Rheumatology

- 1. Manage the care of patients with acute and chronic, common and complex rheumatologic diseases across multiple care settings. *MK*, *PC*, *ICS*, *P*, *PBLI*, *SBP*
- 2. Demonstrate expertise in the performance and interpretation of the musculoskeletal examination. *MK, PC, ICS, P*
- Demonstrate expertise in the indications for and interpretation of diagnostic tests and imaging studies relevant to the evaluation of patients with suspected or established rheumatic and musculoskeletal disease.
 MK, PC, ICS, P
- 4. Prescribe and manage immunomodulatory therapy. *MK, PC, ICS, P, PBLI, SBP*
- Perform procedures including arthrocentesis and injections, compensated polarized microscopy, and interpretation of synovial fluid analysis. MK, PC, ICS, P, PBLI
- 6. Provide rheumatology consultation to other specialties and providers. *MK, PC, ICS, P, PBLI, SBP*
- 7. Demonstrate professional, compassionate and ethical behavior. ICS, P
- 8. Effectively communicate and manage transitions of care with other healthcare providers. *MK, PC, ICS, P*

- 9. Collaborate and work effectively as a member or leader of interprofessional health care teams. *MK, PC, ICS, P, PBLI, SBP*
- 10. Facilitate the learning of patients, families, and members of the interprofessional team. MK, PC, ICS, P
- Enhance and promote patient safety and the quality of health care at both the individual and systems level. *MK, PC, ICS, P, PBLI, SBP*
- 12. Advocate for individual patients. *MK, PC, ICS, P, SBP*
- 13. Contribute to the fiscally sound and ethical management of a practice. *PC, ICS, P, SBP*
- 14. Engage in lifelong learning. *MK, PBLI, SBP*

APPENDIX C. RHEUMATOLOGY CURRICULAR MILESTONES

| 1. Gathers and | synthesizes essential ar | nd accurate information | to define each patient's | clinical problem(s). (PC | 1) |
|----------------|---------------------------|--|--|---|--|
| | | Rheumatolog | y Curricular Milestones | | |
| Number | | By the listed time the f | ellow should be able to | | For this curricular milestone |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular innestone |
| PC1-01 | Obtain and report | Formulate with relevance | Incorporate; Teach others the elements of | | a comprehensive, accurate history, including review of all available records, on |
| | | | | | patients with rheumatic symptoms and signs. |
| | Perform a | and report | Distinguish with relevance; Integrate | Teach others to perform | a comprehensive, accurate physical examination, using |
| PC1-02 | | | | | common and advanced techniques where applicable, |
| | | on patients with rheumatic symptoms and signs. | | | |
| | Order and review | Interpret | Incorporate | Teach others about the clinical application of | diagnostic tests including, but not limited to, |
| DC1 02 | | | | | laboratory, imaging, electrodiagnostic and |
| PC1-03 | | | | | pathologic studies for the evaluation of the patient |
| | | | | | with rheumatic symptoms and signs. |
| | List the steps of | Recognize normal anatomy | Differentiate abnormal findings | Teach others to detect abnormalities | using a standardized approach to the |
| PC1-04 | | | | | interpretation of musculoskeletal plain |
| | | | | | radiographs. |
| | Describe applications, in | dications and limitations | Recognize normal anatomy; Di | fferentiate abnormal findings | using a standardized approach for the |
| PC1-05 | | | | | interpretation of musculoskeletal |
| | | | | | ultrasonography for diagnostic purposes. |

| | Recognize the need to | Without faculty member | collaboratively review |
|--------|-----------------------|------------------------|--------------------------|
| | | prompting, | imaging and tissue |
| PC1-06 | | | specimens with radiology |
| PC1-00 | | | and pathology services, |
| | | | respectively, to enhance |
| | | | patient safety and care |

| 2. Develops an | 2. Develops and achieves comprehensive management plan for each patient. (PC2) | | | | | |
|----------------|--|---|--|---|--|--|
| | | Rheumatolog | y Curricular Milestones | | | |
| Number | | By the listed time the f | ellow should be able to | | For this curricular milestone | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | |
| PC2-01 | List the components of | For uncomplicated presentations construct and implement | For complicated presentations construct and implement | Teach others to formulate | a comprehensive treatment plan, based on clinical evidence, clinical context, | |
| PC2-01 | | | | | and patient preferences, counsel patients, and assess response to therapy. | |
| PC2-02 | Describe state and federal regulations for prescription of controlled substances as part of | Describe non-pharmacologic and pharmacologic components of; Implement, and monitor response to therapy, patient compliance, and detect signs and symptoms indicative of analgesic abuse as part of | | | a pain management strategy of the care plan. | |
| | | | | | | |
| PC2-03 | Describes indications and potential adverse events of | Obtains verbal or written informed consent for treatment with | Prescribe, monitor and assess response to | Teaches others to prescribe, monitor and assess response to | pharmacotherapy, including immunomodulatory agents, used in the management of | |
| | | | | | patients with rheumatic diseases. | |
| PC2-04 | In comparison to adults, discuss the similarities and differences in drug disposition and its consequences regarding; List the currently used | | Prescribe and adj | just accordingly | pharmacotherapies for use in children and adolescents with rheumatic diseases. | |
| | | | | | | |
| PC2-05 | _ | pharmacokinetics that occur e affect | Prescribe and adjust appropriately | Teach others about | therapeutic and management strategies in | |
| | | | | | the aging population with | |

| | | | | | rheumatic diseases. |
|--------|----------------------------|--|---------------------|-----------------------------|--|
| PC2-06 | List options for | Describe applications and indications for | Incorporate | Teach others to incorporate | exercise and other rehabilitation strategies in |
| PC2-06 | | | | | the care of patients with rheumatic disorders. |
| | With attending supervision | With attending supervision for complicated presentations | Indepen Teach ot | | formulate and implement a management plan for patients with rheumatic |
| PC2-07 | | | | | emergencies (including organ or life threatening conditions), with a need for emergent, urgent or changes in level or goals of care. |

| 8. Manages patients with progressive responsibility and independence. (PC3) | | | | | |
|---|---|---|--|---|--|
| | | Rheumatolog | y Curricular Milestones | | |
| Number | | By the listed time the f | fellow should be able to | | For this curricular milestone |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular innestone |
| PC3-01 | Describe the potential manifestations of | Formulate plans to screen for and manage | Implement and monitor plans for | Teach others to recognize and manage | disease-related exacerbations and the influence of comorbid illness during the provision of longitudinal and customized care to patients with rheumatic diseases. |
| PC3-02 | Identify | Formulate plans to screen, assess severity, and manage | Implement and monitor plans to screen, assess severity, and manage | Teach others to recognize and manage | disease- and treatment- related complications that may lead to long term morbidity, including the consideration for implications of comorbid diseases and the effects of aging. |
| PC3-03 | Recognize | Develop strate | egies to manage | Implement strategies to manage | the psychosocial aspects of rheumatic diseases. |
| PC3-04 | List and describe the utility of | Incorporate into practice | Teach others to incor | porate into practice | the varied validated instruments in the assessment of pain, disease |

| 4a. Demonstrates skill in performing and interpreting invasive procedures. (PC4a) NOTE: PC4a and PC4b (non-invasive | | | | | | |
|---|----------------------------|---|------------------------|-----------------------------------|--|--|
| procedures) converted to single template of Skill in performing procedures | | | | | | |
| Rheumatology Curricular Milestones | | | | | | |
| Number | | By the listed time the fe | llow should be able to | - | For this curricular milestone | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular innestone | |
| PC4-01 | With attending supervision | Independently; Teach others to | | | obtain verbal or written informed consent from | |
| 10401 | | |] | | patient or caregiver for procedures. | |
| PC4-02 | With attending supervision | With attending assistance for previously u | | Independently; Teach others to | perform procedures including arthrocentesis and | |
| PC4-02 | | | | | joint and soft tissue injections. | |
| PC4-03 | With attend | perform procedures including arthrocentesis and joint and soft tissue injections with ultrasound | | | | |
| | | | | | guidance, when appropriate and feasible. | |
| PC4-04 | With attending supervision | Independently | Teach others to | | perform compensated polarized microscopy to examine and interpret synovial fluid. | |

| Requests a | nd provides consultative | care. (PC5) | | | | | | | | |
|-------------------|---|---|---|-----------|---|--|--|--|--|--|
| | Rheumatology Curricular Milestones | | | | | | | | | |
| Number | | By the listed time the f | ellow should be able to | | For this curricular mileston | | | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular mileston | | | | | |
| PC5-01 | Identify the indications to | Proactively | Teach others why, when, and how to | | refer to other healthcare providers for the co- | | | | | |
| PC3-01 | | | | | management of patients with rheumatic disease. | | | | | |
| PC5-02 | Recognize the tissues commonly considered for | List the indications, expected risks and benefits, and available alternatives for | Implement plans to refer for; Teach others how to incorporate | | diagnostic biopsies (including, but not limited to temporal artery, renal, lung | | | | | |

| | | | | | | | | | muscle, nerve, skin, minor salivary gland, and brain) in the evaluation of rheumatic diseases, and refers when indicated and appropriate. |
|--------|-------------------------|----------|------------------|-------------|---------------|-----|----------------|-----|---|
| | | Identify | opportunities fo | or referral | | Ref | er when indica | ted | to clinical registries and |
| PC5-03 | | | | | | | | | trials. |
| | | | | | | | | | |
| | With attending supervis | sion | | | Independently | | | | provide consultation when |
| | | | | | | | | | requested, in support of the |
| | | | | | | | | | primary care relationship, for patients with rheumatic |
| | | | | | | | | | symptoms and signs and |
| | | | | | | | | | symptoms and signs and |
| PC5-04 | | | | | | | | | appropriately integrate |
| PC5-04 | | | | | | | | | appropriately integrate recommendations from |
| PC5-04 | | | | | | | | | appropriately integrate |

| 6. Possesses Cl | inical knowledge (MK1) | | | | |
|-----------------|------------------------------------|--|---|--------------|--|
| | | Rheumatolog | y Curricular Milestones | | |
| Number | | By the listed time the f | fellow should be able to | | For this curricular milestone |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular innestone |
| | Demonst | rate basic | Demonstrate co | omprehensive | knowledge of the relevant |
| MK1-01 | | | | | structure and function of the musculoskeletal system, immune system and basic science for describing the pathophysiology of rheumatologic conditions. |
| MK1-02 | Acknowledge the indications for | Independently distinguish indications for | Independently formulate specific consultative questions for | | referrals to other subspecialists and ancillary services including orthopedics and rehabilitation medicine. |

| MK1-03 | List Explain | Differentiate subtle differences in | relevant mechanisms of action and potential adverse effects of agents used in the management of patients with rheumatologic conditions. |
|--------|--------------------------------------|---|--|
| MK1-04 | Report on | | the anatomy, physiology and management of pain in patients with rheumatologic conditions. |
| MK1-05 | | Describe in detail Explain the significance of | similarities and differences of the clinical presentation and management between adults and children with rheumatic conditions. |
| MK1-06 | In uncomplicated cases, construct | In highly complex cases, with multi-system involvement, construct | a differential diagnosis for rheumatologic conditions, including consideration of non-rheumatic diseases. |
| MK1-07 | Demonstrate basic | Demonstrate comprehensive | knowledge regarding the need for preventive care in patients with rheumatic conditions. |
| MK1-08 | Demonstrate basic | Demonstrate comprehensive | knowledge to evaluate complex rheumatic diseases in the setting of multiple coexistent conditions, including the effects of aging. |
| MK1-09 | Demonstrate basic | Demonstrate comprehensive | knowledge of socio- behavioral sciences including but not limited to health care economics and medical ethics. |

| 7. Knowledge o | 7. Knowledge of diagnostic testing and procedures. (MK2) | | | | | | | | |
|---|--|--|--|--|--|--|--|--|--|
| | Rheumatology Curricular Milestones | | | | | | | | |
| Number | By the listed time the fellow should be able to | | | | | | | | |
| Number6 months12 months18 months24 monthsFor this curricular milester | | | | | | | | | |

| | Identify | C | escribe | Dif | ferentiate | Tea | ch | indications, risks and |
|--------|----------|--------|---------|---------|------------|-----------------|---------------|---|
| | |] | | | | | | benefits of rheumatologic |
| | | | | | | | | diagnostic testing, including but not limited to |
| | | | | | | | | immunoassays, synovial fluid |
| MK2-01 | | | | | | | | analysis, routine blood |
| | | | | | | | | chemistries, hematologic |
| | | | | | | | | studies, coagulation studies, |
| | | | | | | | | radiographs, and DXA |
| | | | | | | | | scanning. |
| | | Explai | n 📃 🗌 | | | Teach others ab | out | major findings and |
| | | | | | | | | interpretation of rheumatologic diagnostic |
| | | | | | | | | testing, including but not |
| | | | | | | | | limited to immunoassays, |
| MK2-02 | | | | | | | | synovial fluid analysis, |
| | | | | | | | | routine blood chemistries, |
| | | | | | | | | hematologic studies, coagulation studies, |
| | | | | | | | | radiographs, and DXA |
| | | | | | | | | scanning. |
| | List | t | | Explain | | | Differentiate | indications, risks and |
| | |] | | | | | | benefits for more advanced |
| | | | | | | | | diagnostic tests including imaging techniques (isotopic, |
| | | | | | | | | PET, CT and MRI scanning, |
| MK2-03 | | | | | | | | angiography and |
| | | | | | | | | musculoskeletal ultrasound) |
| | | | | | | | | and pathologic examination |
| | | | | | | | | of tissues involved with rheumatic diseases. |
| | | Explai | n | | | Teach others | | major findings and |
| | | | <u></u> | | | | | interpretation of more |
| | | | | | | | | advanced diagnostic tests |
| | | | | | | | | including imaging techniques |
| MK2-04 | | | | | | | | (isotopic, PET, CT and MRI |
| | | | | | | | | scanning, angiography and musculoskeletal ultrasound) |
| | | | | | | | | and pathologic examination |
| | | | | | | | | of tissues involved with |
| | | | | | | | | of tissues involved with |

| 8. Scholarship | . (MK3) | | | | |
|----------------|------------------------------|--|---|--|---|
| | | Rheumatolog | y Curricular Milestones | | |
| Number | | For this curricular milestone | | | |
| Number | 6 months | 12 months | 18 months | 24 months | |
| N4//2 04 | Demonstrate basic | | Demonstrate comprehensive | | knowledge of principles |
| MK3-01 | | | | | underlying critical appraisal of the medical literature. |
| MK3-02 | List | Describe | Explain the signal Implement a | | basic biostatistical testing and epidemiological |
| WIK5-02 | | | | | principles. |
| MK3-03 | Describe principles underlyi | ng research study design for | Generate a hypothesis and select methodology for | Perform data collection and analysis for; Disseminate findings of; Recognize components of grant writing and submission for | a scholarly project related to clinical practice, quality improvement, patient safety, medical education or research in collaboration with a faculty mentor. |
| | | | | | |
| MK3-04 | | Prepare and submit an abstrac | t | Prepare and submit a peer- reviewed manuscript; Prepare and submit a non- peer reviewed manuscript for publication (e.g. clinical review, book chapter) | to demonstrate effective scientific writing skills. |
| | | | | | |
| MK3-05 | | onferences, including but not d rounds, lay education, local al meetings | Present an abstract locally, regionally, or nationally | | to disseminate scholarly work. |
| | | | | | principles of informed |
| MK3-06 | List | Describe; Explain the significance of; Enact | | | principles of informed consent as it pertains to investigation, involving human subjects. |
| | | | | | |

9. Works effectively within an interprofessional team (e.g., with peers, consultants, nursing, ancillary professionals, and other support personnel). (SBP1)

| | | Rheumatology | / Curricular Milestones | | | | | |
|---------|---|---------------------------------------|------------------------------|--------------------------|--|--|--|--|
| Number | By the listed time the fellow should be able to | | | | | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | | | |
| SBP1-01 | Acknowledge the contributions from | Actively participate and work with |] | | health care providers from varied disciplines to promote patient-centered care. | | | |
| SBP1-02 | Recognize the varied | Explain the contributions of | Participate in th | e activities of | health care providers who work to promote patient safety and to identify risks for and strategies to prevent medical errors. | | | |
| SBP1-03 | List the individual components that contribute to | Ascribe levels of complexity to | the components that comprise | Implement | appropriate coding based on documentation and reimbursement policies. | | | |
| SBP1-04 | Decsribes | Differentia | ates among | Works effectively within | the spectrum of practice models for health care delivery, including the fundamentals of office and personnel management. | | | |

| 10. Recognizes | 10. Recognizes system error and advocates for system improvement. (SBP2) | | | | | | | | | | |
|------------------------------------|---|---|---|-----------|--|--|--|--|--|--|--|
| Rheumatology Curricular Milestones | | | | | | | | | | | |
| Number | | By the listed time the fe | ellow should be able to | | For this curricular milestone | | | | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | | | | | | |
| SBP2-01 | Recognize situations leading to inefficiencies, safety concerns and/or preventable medical errors when | Participate in a system level quality improvement initiatives while | Design and implement a system level quality improvement initiative while | | partnering with other healthcare teams and professionals to improve the quality of care and patient | | | | | | |
| | | | | | safety within the system. | | | | | | |
| SBP2-02 | Demonstra | te ability to | Assist others within o Assist the | • | recognize opportunities to address causes of disparity in | | | | | | |
| SDF2-U2 | | | | | disease and healthcare delivery. | | | | | | |

| 11. Identifies forces that impact the cost of health care, and advocates for and practices cost-effective care. (SBP3) | |
|--|--|
| Rheumatology Curricular Milestones | |

| Number | | By the listed time | By the listed time the fellow should be able to | | | |
|----------|---|-----------------------|---|--|--|--|
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | |
| SBP3-01 | Recognize the necessity to integrate | Participate i | n decisions that reflect | Independently incorporate considerations of | cost awareness and cost benefit analysis for disease | |
| 30F 3-01 | | | | | specific care as well as in individual patients. | |
| | Recognize | | / ways to address; ate for change of | Implement measures to correct | barriers impacting patient care, including socio- | |
| SBP3-02 | | | | | economic factors, healthcare literacy, medical disability and health care insurance coverage. | |
| | ldentify | Describe the impact c | on health care cost and access by | Leverage the advantages, for individual patients, of | the various health care settings (academic | |
| SBP3-03 | | | | | /public/private/VA) and stakeholders in the healthcare economy. | |

| 12. Transition | 12. Transitions patients effectively within and across health delivery systems. (SBP4) | | | | | | | | | | |
|------------------------------------|--|-------------------------------|---------------------------------|---|---|--|--|--|--|--|--|
| Rheumatology Curricular Milestones | | | | | | | | | | | |
| Number | By the listed time the fellow should be able to | | | | | | | | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | | | | | | |
| CDD4 01 | Identify the providers, therapies, and potential obstacles to successfully | Discuss strategies to overcom | e the obstacles to successfully | Implement strategies to successfully | coordinate care across multiple delivery systems, including ambulatory, | | | | | | |
| SBP4-01 | | | | | subacute, acute, rehabilitation and skilled nursing facilities. | | | | | | |

| 3. Monitors practice with a goal for improvement. (PBLI1) | | | | | | | | |
|---|---|--|---------------------------|-----------|---|--|--|--|
| | | Rheumatolog | y Curricular Milestones | | | | | |
| Number | By the listed time the fellow should be able to | | | | | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular mileston | | | |
| PBLI1-01 | Acknowledge the importance of reflection to | Routinely reflect on clinical interactions to; Describe his or her own efforts to | Seek resources to address | | identify(ied) knowledge or skills gaps to enhance future clinical interactions. | | | |
| | | | | | | | | |

| | | Recognize | | Implement | ways to improve his/her role |
|----------|--|-----------|--|-----------|--|
| PBLI1-02 | | | | | in the effective management of a practice. |

| 14. Learns and | improves via performa | nce audit. (PBLI2) | | | |
|----------------|-------------------------|-------------------------------------|-------------------------|---|---|
| | | Rheumatology | Curricular Milestones | | |
| Number | | By the listed time the fe | ellow should be able to | | For this curricular milestone |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular innestone |
| | | | | Demonstrate through | learns from errors. |
| | Can describe what s/he | Independently identify | and describe what s/he | actions taken to improve | |
| PBLI2-01 | Call describe what syne | | and describe what sine | the system or processes of | |
| | | | | care that s/he | |
| | | | | | |
| PBLI2-02 | | Identify an area of inquiry to dire | ct | Design the method for; Perform and analyze; Reflect on and hypothesize an explanation for deficiencies found (including doctor-related, system-related, and patient-related factors) through; Change practice based on results of | an audit of a panel of patients using standardized, disease-specific, and evidence-based criteria. |
| | | | | | |

| 15. Learns and | improves via feedback. (| PBLI3) | | | | | | | |
|----------------|--|-----------------------------|----------------------|-----------|---|--|--|--|--|
| | Rheumatology Curricular Milestones | | | | | | | | |
| Number | | By the listed time the fell | ow should be able to | | For this curricular milestone | | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | | | | |
| PBLI3-01 | Accept and r Actively seek an Develop plans for practice | nd reflect on; | | | feedback from all members of the health care team including faculty, peers, students, nurses, allied health workers, patients and their advocates. | | | | |

| 16. Learns and | improves at the point of | care. (PBLI4) | | | |
|----------------|---|---|-------------------------|-----------|---|
| | | Rheumatology | Curricular Milestones | | |
| Number | | By the listed time the fe | ellow should be able to | | For this curricular milestone |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone |
| PBLI4-01 | Identify basic knowledge gaps and seek | In all cases, independently construct and pursue |] | | answers to clinical questions, and performs self-reflection to incorporate learning for future clinical encounters. |
| PBLI4-02 | Independently | Teach others to | | | use(s) technology to manage information (HIPAA compliant), support patient care decisions using evidence-based medicine and enhance both patient and physician education. |
| PBLI4-03 | With prompting from faculty | Independently |] | | maintains awareness of the situation in the moment, and responds to meet situational needs. |
| PBLI4-04 | Customizes manag Determines ar | |] | | clinical evidence for individualized patient care. |

17. Has professional and respectful interactions with patients, caregivers, and members of the interprofessional team (e.g., peers, consultants, nursing, ancillary professionals, and support personnel). (PROF1)

| | | Rheumatology C | Curricular Milestones | | |
|----------|--|---|-----------------------|-----------|---|
| Number | | By the listed time the felle | ow should be able to | | For this curricular milestone |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular innestone |
| PROF1-01 | Recognize and manage differe to Recognize and manage differ members of the interp Provide constructive feedba health care | ; ences of opinion with other professional team to; ck to other members of the | | | demonstrate respectful professional interactions. |
| | Provide responsible team | | | | demonstrate respect for |
| PROF1-02 | leadership to | | | | patient dignity and |
| | | | | | autonomy. |

| | Recognize, respond to, and report impairment in | as a demonstration of commitment to providing |
|----------|---|---|
| PROF1-03 | colleagues or substandard care via peer review process | safe patient care. |
| | | |

| | | Rheumatology | Curricular Milestones | | |
|----------|--|---|--|-----------|--|
| Number | | By the listed time the fe | llow should be able to | | For this curricular mileston |
| Number | 6 months | 12 months | 18 months | 24 months | |
| PROF2-01 | Demonstrates appropriate professional appearance (1 month); Recognize the scope of his/her abilities and ask for supervision and assistance appropriately; When indicated, identify and assist colleagues in need of assistance in the provision of duties | Through his/her actions, serve as a professional role model for peers and learners | Contribute to the fiscally sound practice of an office | | as demonstration of personal accountability. |
| | | | | | |
| PROF2-02 | Respond promptly and appropriately to clinical responsibilities including but not limited to calls and pages; Carry out timely interactions with colleagues, patients, and their designated caregivers | Ensure prompt completion of clinical, administrative, curricular and research- related tasks | | | as a demonstration of the professional attribute of accessibility. |

| 19. Responds | 19. Responds to each patient's unique characteristics and needs. (PROF3) | | | | | | | |
|--------------|--|-------------------------------|-----------|-----------|-------------------------------|--|--|--|
| | Rheumatology Curricular Milestones | | | | | | | |
| Number | By the listed time the fellow should be able to | | | | For this considerations | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | | | |
| PROF3-01 | Represent individual patient | Address disparities in health | | | as a demonstration of being | | | |

| | needs; Show empathy and compassion to all patients; Take responsibility for situations where public health supersedes individual privacy (e.g. reportable infectious diseases) | care among populations that may impact patient care | an advocate for all patients. |
|----------|--|--|---|
| | | | |
| PROF3-02 | Treat patients with dignity, civility and respect, regardless of race, culture, gender, sexual orientation, socioeconomic status, literacy, and religious beliefs; Make efforts to support (physical, psychological, social, and spiritual) patients with acute and chronic, basic and complex rheumatic diseases and their caregivers. | | as a demonstration of showing compassion and respect to patients. |

| | | Rheumatology | Curricular Milestones | | |
|----------|---------------------------------|---------------------------|------------------------|-----------|------------------------------|
| Number | | By the listed time the fe | llow should be able to | | For this curricular mileston |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular inneston |
| | Document and report clinical | | | | as a demonstration of |
| | and research information | | | | adhering to basic ethical |
| | truthfully; | | | | principles. |
| | Follow formal policies; | | | | |
| | Accept personal errors and | | | | |
| PROF4-01 | honestly acknowledge them; | | | | |
| PROF4-01 | Maintain patient | | | | |
| | confidentiality; | | | | |
| | Uphold ethical expectations | | | | |
| | of clinical, scholarly activity | | | | |
| | and research including | | | | |
| | maintenance of up-to-date | | | | |

| | certifications for all professional activities | |
|----------|---|-----------------------------|
| | | |
| | Maintain and monitor | manage conflicts of interes |
| | patient care relationships | |
| | with colleagues, members of | |
| | the interprofessional team | |
| | and office staff to; | |
| | Use technology and social | |
| | media appropriately to; | |
| PROF4-02 | Maintain ethical | |
| | relationships with industry | |
| | to; | |
| | Addresses personal, | |
| | psychological, and physical | |
| | limitations that may affect | |
| | professional performance to | |
| | | |

| 21. Communicates effectively with patients and caregivers. (ICS1) | | | | | | |
|---|--|---|---------------------------------|-------------------------|---|--|
| Rheumatology Curricular Milestones | | | | | | |
| Number | | For this surrigular milestone | | | | |
| | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | |
| ICS1-01 | Use nonverbal skills, and without interruption; Ask thoughtful questions based on ability to | | | | listen carefully to patients and caregivers to create rapport and build a therapeutic relationship. | |
| ICS1-02 | Use plain language, avoiding technical medical terms, to; Appropriately use an interpreter to | Encourage questions, answering clearly, incorporating new insights to | | | explain and counsel patients and caregivers about their problems, proposed examinations and treatments, and findings. | |
| ICS1-03 | Recognize the need to | Incorporate patient | Solicit and incorporate patient | Solicit and incorporate | share decision-making in | |

| | incorporate patient preferences to | preferences to | preferences surrounding uncomplicated situations to | patient preferences surrounding ambiguous or | both diagnostic and therapeutic scenarios. |
|---------|---------------------------------------|-----------------------------|--|---|--|
| | | | | controversial situations to | |
| | | | | | |
| | Demonstrate sensitivity to | Actively seek to understand | Integrate into evaluation and management plans | | differences in patients including, but not limited to |
| ICS1-04 | | | | | race, culture, gender, sexual orientation, socioeconomic status, literacy, religious beliefs. |

| 22. Communicates effectively in interprofessional teams (e.g., with peers, consultants, nursing, ancillary professionals, and other | | | | | | |
|---|---|---|---|--|--|--|
| support personnel). (ICS2) Rheumatology Curricular Milestones | | | | | | |
| | By the listed time the fellow should be able to | | | | | |
| Number | 6 months | 12 months | 18 months | 24 months | For this curricular milestone | |
| | Describe the importance of | Proactively initiate | | | communication with other | |
| ICS2-01 | | | | | healthcare providers in order to maintain appropriate continuity during transitions of care, including from pediatric to adult rheumatology care. | |
| ICS2-02 | Recognize the roles and acknowledge the contributions of individuals in support of | Interact, adapting and shifting roles as necessary, in support of | Initiate problem solving for; Assume a leadership role in the education of all members in support of | | productive interaction within interprofessional teams. | |
| ICS2-03 | Utilize common technologies for | | tion technology, and verbal and al skills for | Role model proficiency in tailored topic selection, presentation technology, and verbal and nonverbal skills for | effective presentation for the specific audience. | |
| | | | | | | |

| 23. Appropriate utilization and completion of health records. (ICS3) | | | | |
|--|---|-------------------------------|--|--|
| Rheumatology Curricular Milestones | | | | |
| Number | By the listed time the fellow should be able to | For this curricular milestone | | |

| | 6 months | 12 months | 18 months | 24 months | |
|---------|-----------------------------|-------------------------------|-----------------------------|-----------|------------------------------|
| | | Adjust communication on | | | timely and legible authentic |
| | Document through | the basis of context, | Organize complex cases into | | documentation that includes |
| 1052-01 | templates/scripts to create | audience and/or situation for | relevant and succinct, | | a differential diagnosis and |
| ICS3-01 | | relevant and succinct, | | | clinical reasoning, and |
| | | | | | support for the appropriate |
| | | | | | level of reimbursement. |

APPENDIX D. RHEUMATOLOGY TOOLBOX: ACTIVITIES AND ASSESSMENTS

Rheumatology Toolbox for Tracking of Curricular Milestone Implementation

Directions: The Curricular Milestones are formatted in two different ways (Appendix C and below for the Rheumatology Toolbox). Utilizing the two far right columns in the Curricular Milestones tables, provided in the Rheumatology Toolbox, you may populate activities and assessment tools specific to your program that encompass each Curricular Milestone. You may utilize the provided list of activities and assessments and supplement with others that are unique to your program.

Activities

| Experience | Activity |
|------------------------|---|
| Clinical experience in | General Rheumatology Continuity Clinic |
| mentored setting | |
| | Outpatient clinic |
| | o VA |
| | • Satellite office |
| | Inflammatory arthritis Gout |
| | o SLE |
| | o Scleroderma |
| | o Vasculitis |
| | Myositis |
| | Pediatric Rheumatology |
| | Osteoporosis |
| | Rheumatology/Dermatology |
| | Rheumatology/Pulmonary |
| | Musculoskeletal ultrasound |
| | o Other |
| | Inpatient consult service (by site) |
| | Inpatient Consult Service (by Site) |
| | Elective |
| | Physical Medicine and Rehab |
| | Sports medicine |
| | Orthopaedics |
| | Pediatric orthopaedics |
| | PT/OT Podiatry |
| | |
| | Pain management Rheumatology private practice |
| | • Other |
| Committee | Participation on committee |
| participation | Division of Rheumatology |
| | Department of Medicine |
| | o Regional |
| | o National |
| Didactics: Large group | Rheumatology Grand Rounds |
| Diadolioon Laigo group | Medicine Grand Rounds |
| | Rheumatology Core Curriculum Conference |
| | Evidence-Based Medicine Conference |
| | Rheumatology Journal Club |
| | Basic Science Journal Club |
| | Rheumatology Research Conference |
| | Basic Science Conference |
| | Immunology Conference |
| | Rheumatology/Radiology |
| | Rheumatology/Pathology |
| | Professors Rounds |
| | Rheumatology Case Conference |
| | Other Grand Rounds(Other interview i |
| | Other interdisciplinary conference |
| | Summer Rheumatology Review |
| | Certificate/Degree program |
| | Attendance at |
| | Land Crasick, Cartananaa |
| | Local Specialty Conferences |
| | Regional Specialty Conferences |
| | Regional Specialty Conferences National Conferences |
| | Regional Specialty Conferences |

| | ACR SOTA | | | |
|------------------------|--|--|--|--|
| Didactics: Small group | Faculty facilitated group discussion | | | |
| | Workshop participation | | | |
| Self study | Self Study Module | | | |
| | Independent Readings | | | |
| | o Textbook | | | |
| | Journal articles | | | |
| | Internet based research | | | |
| | Internet based study | | | |
| | Web-based modules | | | |
| | o Other | | | |
| Fellow projects and | Presentation by Fellow | | | |
| presentations | Rheumatology journal club | | | |
| | Basic science journal club | | | |
| | • Research conference | | | |
| | • Case conference | | | |
| | Rheumatology Grand Rounds | | | |
| | Community education | | | |
| | o Other | | | |
| | Preparation of patient care portfolio | | | |
| | Clinical research project | | | |
| | Basic science research project | | | |
| | • QI | | | |
| | Patient safety project | | | |
| | Scientific writing | | | |
| | Abstract presentation | | | |
| | o Poster | | | |
| | o Podium | | | |
| Simulation | Simulation with models | | | |
| | Simulation with standardized patients | | | |

Assessment Tools

| Methods | Rheumatology Assessment Tools |
|------------------------|---|
| Anatomic model | Joint simulator |
| | Cadaver lab |
| Direct Observation | Mini CEX (clinical) |
| | Mini-PEX (procedure) |
| ACR In training exam | |
| Multisource | Self- assessment |
| assessment | Faculty evaluations (rotations) |
| | Faculty evaluations (3, 6 mo) |
| | Research mentor evaluation |
| | 360 degree (administrative, nursing, health professionals, technical staff) |
| | • Peer |
| | Patient evaluations |
| | Procedural Competency Assessment (arthrocentesis evaluation form, 6 |
| | months) |
| | Semiannual Program Director review |
| | ACGME Reporting Milestones by Clinical Competency Committee |
| | |
| Objective structured | |
| clinical exam (OSCE) | |
| Videotaped or | |
| recorded assessment | |
| Oral Examination | |
| Practice/billing audit | Medical documentation review |
| Presentation skills | Feedback forms for presentations |
| | Rheumatology Journal Club |
| | Basic Science Journal Club |
| | Grand Rounds |
| | Case Conference |
| | Morbidity and Mortality |
| Project assessment | • QI |

| by faculty | Research |
|---------------------------------|------------------|
| Record/chart review | |
| Trainee experience narrative | Reflection |
| Review case/procedure log | |
| Review of drug prescribing | |
| Review of patient | QI project |
| outcomes | Registry review |
| Role play or simulations | |
| Simulations/models | Joint injection |
| Standardized patient | |
| exams | |
| Structured case | |
| discussions | |
| | Portfolio review |

Rheumatology Curricular Milestones Tables

MEDICAL KNOWLEDGE

| | | | Rheumato | logy Curricular Milestones | Your Train | ing Program |
|-------------------------------------|---------|-----------------------------|---|---|------------|------------------|
| Subspecialty Reporting Milestone | Number | By this time (months) | The fellow should be able to | For this curricular milestone | Activities | Assessment Tools |
| Clinical Knowledge | | 12 | Demonstrate basic | knowledge of the relevant structure and function of the musculoskeletal system, | | |
| (MK1) | MK1-01 | 24 | Demonstrate comprehensive | immune system and basic science for describing the pathophysiology of rheumatologic conditions. | | |
| | | 6 | Acknowledge the indications for | | | |
| | MK1-02 | 12 | Independently distinguish indications for | referrals to other subspecialists and ancillary services including orthopedics and rehabilitation medicine. | | |
| | WIK1-UZ | 18 | Independently formulate specific consultative questions for | | | |
| | | 6 | List | | | |
| | MK1-03 | 12 | Explain | relevant mechanisms of action and potential adverse effects of agents used in the management of patients with rheumatologic conditions. | | |
| - | | 18 | Differentiate subtle differences in | | | |
| | MK1-04 | 12 | Report on | the anatomy, physiology and management of pain in patients with rheumatologic conditions. | | |
| | | 18 | Teach others | | | |
| | | 12 | List | similarities and differences of the clinical presentation and management between adults and children with rheumatic conditions. | | |
| | MK1-05 | 18 | Describe in detail | | | |
| | | 24 | Explain the significance of | | | |
| | | 6 | In uncomplicated cases, construct | | | |
| | | 12 | In cases demonstrating increasing complexity, construct | a differential diagnosis for rheumatologic conditions, including consideration of non-rheumatic diseases. | | |
| | MK1-06 | 18 | In highly complex cases, with multi- system involvement, construct | | | |
| | | 24 | Teach others to construct | | | |
| | MK1-07 | 12 | Demonstrate basic | knowledge regarding the need for preventive care in patients with rheumatic conditions. | | |
| | WIKT-07 | 18 | Demonstrate comprehensive | Conditions. | | |
| | MK1-08 | 12 | Demonstrate basic | knowledge to evaluate complex rheumatic diseases in the setting of multiple | | |

| | | | Demonstrate comprehensive | coexistent conditions, including the effects of aging. | |
|--|----------|----|---|--|--|
| | | 18 | | | |
| | MK1-09 | 12 | Demonstrate basic | knowledge of socio-behavioral sciences including but not limited to health care economics and medical ethics. | |
| | | 24 | Demonstrate comprehensive | | |
| Knowledge of Diagnostic Testing and | | 6 | Identify | | |
| Procedures (MK2) | | 12 | Describe | indications, risks and benefits of rheumatologic diagnostic testing, including but | |
| | MK2-01 | 18 | Differentiate | not limited to immunoassays, synovial fluid analysis, routine blood chemistries, hematologic studies, coagulation studies, radiographs, and DXA scanning. | |
| | | 24 | Teach | | |
| | N#2 02 | 12 | Explain | major findings and interpretation of rheumatologic diagnostic testing, including but not limited to immunoassays, synovial fluid analysis, routine blood | |
| | MK2-02 | 24 | Teach others about | chemistries, hematologic studies, coagulation studies, radiographs, and DXA scanning. | |
| | | 6 | List | indications, risks and benefits for more advanced diagnostic tests including | |
| | MK2-03 | 18 | Explain | imaging techniques (isotopic, PET, CT and MRI scanning, angiography and musculoskeletal ultrasound) and pathologic examination of tissues involved with | |
| | | 24 | Differentiate | rheumatic diseases. | |
| | 14//2 04 | 12 | Explain | major findings and interpretation of more advanced diagnostic tests including imaging techniques (isotopic, PET, CT and MRI scanning, angiography and | |
| | MK2-04 | 24 | Teach others about | musculoskeletal ultrasound) and pathologic examination of tissues involved with rheumatic diseases. | |
| Scholarship (MK3) | MK3-01 | 6 | Demonstrate basic | knowledge of principles underlying critical appraisal of the medical literature. | |
| | | 24 | Demonstrate comprehensive | | |
| | | 6 | List | | |
| | MK2 02 | 12 | Describe | basic biostatistical testing and epidemiological principles. | |
| | MK3-02 | 24 | Explain the significance of | | |
| | | 24 | Implement and interpret | | |
| | | 12 | Describe principles underlying research study design for | | |
| | MK2 02 | 18 | Generate a hypothesis and select methodology for | a scholarly project related to clinical practice, quality improvement, patient | |
| | MK3-03 | 24 | Perform data collection and analysis for | safety, medical education or research in collaboration with a faculty mentor. | |
| | | 24 | Disseminate findings of | | |
| | | 24 | Recognize components of grant writing and submission for | | |
| | | 18 | Prepare and submit an abstract | | |
| | | | | to demonstrate effective scientific writing skills. | |
| | MK3-05 | 24 | Prepare and submit a peer-reviewed manuscript | | |
| | | | | | |

| | | 24 | Prepare and submit a non-peer reviewed manuscript for publication (e.g. clinical review, book chapter) | | |
|--|--------|----|--|---|--|
| | MK3-06 | 12 | Effectively present orally at conferences, including but not limited to rheumatology grand rounds, lay education, local and national meetings | to disseminate scholarly work. | |
| | | 18 | Present an abstract locally, regionally, or nationally | | |
| | | 6 | List | principles of informed consent as it pertains to investigation, involving human | |
| | MK3-07 | 12 | | | |
| | | 12 | Explain the significance of | | |
| | | 12 | Enact | | |

PATIENT CARE

| | | | Rheumato | Your Traini | ng Program | |
|---|--------|-----------------------------|--|--|------------|------------------|
| Subspecialty Reporting Milestone | Number | By this time (months) | The fellow should be able to | For this curricular milestone | Activities | Assessment Tools |
| Gathers and synthesizes | | 6 | Obtain and report | | | |
| essential and accurate information to define each patient's clinical problem(s). (PC1) | PC1-01 | 12 | Formulate with relevance | a comprehensive, accurate history, including review of all available records, | | |
| | FCI-01 | 18 | Incorporate | on patients with rheumatic symptoms and signs. | | |
| | Ī | 18 | Teach others the elements of | | | |
| | | 12 | Perform and report | | | |
| | | 18 | Distinguish with relevance | a comprehensive, accurate physical examination, using common and advanced | | |
| | PC1-02 | 18 | Integrate | techniques where applicable, on patients with rheumatic symptoms and signs. | | |
| | l t | 24 | Teach others to perform | | | |
| | | 6 | Order and review | | | |
| P | Ī | 12 | Interpret | diagnostic tests including, but not limited to, laboratory, imaging, electrodiagnostic and pathologic studies for the evaluation of the patient with rheumatic symptoms and signs. | | |
| | PC1-03 | 18 | Incorporate | | | |
| | | 24 | Teach others about the clinical application of | | | |
| | | 6 | List the steps of | | | |
| | PC1-04 | 12 | Recognize normal anatomy | using a standardized approach to the interpretation of musculoskeletal plain | | |
| | 101-04 | 18 | Differentiate abnormal findings | radiographs. | | |
| | | 24 | Teach others to detect abnormalities | | | |
| | PC1-05 | 12 | Describe applications, indications and limitations | using a standardized approach for the interpretation of musculoskeletal | | |
| | PC1-05 | 24 | Recognize normal anatomy | ultrasonography for diagnostic purposes. | | |
| | | 24 | Differentiate abnormal findings | | | |
| | PC1-06 | 6 | Recognize the need to | collaboratively review imaging and tissue specimens with radiology and | | |
| | PC1-06 | 12 | Without faculty member prompting, | pathology services, respectively, to enhance patient safety and care | | |
| Develops and achieves | | 6 | List the components of | | | |
| omprehensive nanagement plan for | DC2 01 | 12 | For uncomplicated presentations construct and implement | a comprehensive treatment plan, based on clinical evidence, clinical | | |
| ach patient. (PC2) | PC2-01 | 18 | For complicated presentations construct and implement | context, and patient preferences, counsel patients, and assess response to therapy. | | |
| | † | 24 | Teach others to formulate | | | |

| | | | 1 | | |
|--|----------|----------|--|--|--|
| | | | Describe state and federal regulations for | | |
| | | 6 | prescription of controlled substances as part | | |
| | | | of | | |
| | | | | | |
| | | 12 | Describe non-pharmacologic and | | |
| | PC2-02 | | pharmacologic components of | a pain management strategy of the care plan. | |
| | | | Implement, and monitor response to | | |
| | | | therapy, patient compliance, and detect | | |
| | | 12 | signs and symptoms indicative of analgesic | | |
| | | | abuse as part of | | |
| | | | Describes indications and potential adverse | | |
| | | 6 | events of | | |
| | | 10 | Obtains verbal or written informed consent | | |
| | PC2-03 | 12 | for treatment with | pharmacotherapy, including immunomodulatory agents, used in the | |
| | | 18 | Prescribe, monitor and assess response to | management of patients with rheumatic diseases. | |
| | | 24 | Teaches others to prescribe, monitor and | | |
| | | 24 | assess response to | | |
| | | | In comparison to adults, discuss the | | |
| | | 12 | similarities and differences in drug | pharmacotherapies for use in children and adelessents with the matter | |
| | PC2-04 | | disposition and its consequences regarding | pharmacotherapies for use in children and adolescents with rheumatic diseases. | |
| | | 12 | List the currently used | uiseases. | |
| | | 24 | Prescribe and adjust accordingly | | |
| | | 12 | Discuss how the changes in | | |
| | | 12 | pharmacokinetics that occur with age affect | therapeutic and management strategies in the aging population with rheumatic | |
| | PC2-05 | 18 | Prescribe and adjust appropriately | diseases. | |
| | | 24 | Teach others about | | |
| | | 6 | List options for | exercise and other rehabilitation strategies in the care of patients with rheumatic disorders. | |
| | PC2-06 | 12 | Describe applications and indications for | | |
| | PC2-06 | 18 | Incorporate | | |
| | | 24 | Teach others to incorporate | | |
| | | 6 | With attending supervision | | |
| | PC2-07 | 12 | With attending supervision for complicated presentations | formulate and implement a management plan for patients with rheumatic emergencies (including organ or life threatening conditions), with a need for emergent, urgent or changes in level or goals of care. | |
| | 1 62 07 | 24 | Independently | | |
| | | 24 | Teach others to | | |
| Manages patients with | | 6 | Describe the potential manifestations of | | |
| progressive | | 12 | Formulate plans to screen for and manage | disease-related exacerbations and the influence of comorbid illness during the | |
| responsibility and | PC3-01 | 18 | Implement and monitor plans for | provision of longitudinal and customized care to patients with rheumatic | |
| independence. (PC3) | | 24 | Teach others to recognize and manage | diseases. | |
| | | 6 | Identify | | |
| | | 12 | Formulate plans to screen, assess severity, | disease and treatment related complications that may load to loss terms | |
| | PC3-02 | 12 | and manage | disease- and treatment-related complications that may lead to long term morbidity, including the consideration for implications of comorbid diseases and | |
| | F C3-02 | 18 | Implement and monitor plans to screen, | the effects of aging. | |
| | | | assess severity, and manage | the effects of aging. | |
| | | 24 | Teach others to recognize and manage | | |
| | | 6 | Recognize | | |
| | PC3-03 | 18 | Develop strategies to manage | the psychosocial aspects of rheumatic diseases. | |
| | | 24 | Implement strategies to manage | | |
| | DC2 01 | 6 | List and describe the utility of | the varied validated instruments in the assessment of pain, disease activity, | |
| | PC3-04 | 12 | Incorporate into practice | function, and quality of life over time to monitor and adjust therapy. | |
| Chill in nonforming | | 18 | Teach others to incorporate into practice | | |
| Skill in performing procedures. (PC4) | DC4 04 | 6 | With attending supervision | obtain verbal or written informed consent from patient or caregiver for | |
| procedures. (PC4) | PC4-01 | 12 12 | Independently | procedures. | |
| | <u> </u> | | Teach others to | | |
| | PC4-02 | 6 | With attending supervision | perform procedures including arthrocentesis and joint and soft tissue injections. | |
| | 1 | 18 | With attending assistance for those that are | | |

| [| 1 | | | |
|--------------------------|--------|----|--|--|
| | | | complicated or previously unperformed | |
| | | 24 | Independently | |
| | | 24 | Teach others to | |
| | | 24 | With attending supervision | |
| | | 24 | With attending assistance for those that are | |
| | PC4-03 | 24 | complicated or previously unperformed | perform procedures including arthrocentesis and joint and soft tissue injections |
| | | 24 | Independently | with ultrasound guidance, when appropriate and feasible. |
| | | 24 | Teach others to | |
| | | 6 | With attending supervision | |
| | PC4-04 | 12 | Independently | perform compensated polarized microscopy to examine and interpret synovial fluid. |
| | | 18 | Teach others to | nua. |
| Requests and provides | | 6 | Identify the indications to | |
| consultative care. (PC5) | PC5-01 | 12 | Proactively | refer to other healthcare providers for the co-management of patients with |
| | | 18 | Teach others why, when, and how to | rheumatic disease. |
| | | 6 | Recognize the tissues commonly considered for | |
| | PC5-02 | 12 | List the indications, expected risks and benefits, and available alternatives for | diagnostic biopsies (including, but not limited to, temporal artery, renal, lung, muscle, nerve, skin, minor salivary gland, and brain) in the evaluation |
| | | 18 | Implement plans to refer for | of rheumatic diseases, and refers when indicated and appropriate. |
| | | 18 | Teach others how to incorporate | |
| | | 18 | Identify opportunities for referral | |
| | PC5-03 | 24 | Refer when indicated | to clinical registries and trials. |
| | | 6 | With attending supervision | provide consultation when requested, in support of the primary care relationship, for patients with rheumatic symptoms and signs and |
| | PC5-04 | 24 | Independently | appropriately integrate recommendations from other healthcare providers into the evaluation and management plan. |

PRACTICE-

BASED LEARNING AND IMPROVEMENT

| | Rheumatology Curricular Milestones Your Training I | | | | | Program |
|-------------------------------------|--|------------|--|---|----------|------------------|
| Subspecialty Reporting Milestone | Number | Activities | Activities | For this curricular milestone Act | tivities | Assessment Tools |
| Monitors Practice | | 6 | Acknowledge the importance of reflection to | | | |
| vith goal for mprovement (PBLI1) | | 12 | Routinely reflect on clinical interactions to | | | |
| improvement (PBLII) | PBLI1-01 | 12 | Describe his or her own efforts to | identify(ied) knowledge or skills gaps to enhance future clinical interactions. | | |
| | | 18 | Seek resources to address | | | |
| | PBLI1-02 | 18 | Recognize | | | |
| | | 24 | Implement | ways to improve his/her role in the effective management of a practice. | | |
| Learns and improves | | 6 | Can describe what s/he | | | |
| via performance audit. (PBLI2) | PBLI2- | 18 | Independently identify and describe what s/he | learns from errors. | | |
| | 01 | 24 | Demonstrate through actions taken to improve the system or processes of care that s/he | | | |
| | PBLI2- | 18 | Identify an area of inquiry to direct | an audit of a panel of nationte using standardized, disease specific, and | | |
| | 02 | 24 | Design the method for | an audit of a panel of patients using standardized, disease-specific, and evidence-based criteria. | | |
| | 52 | 24 | Perform and analyze | evidence-based citteria. | | |

| | | 24 | Reflect on and hypothesize an explanation for deficiencies found (including doctor- related, system-related, and patient- related factors) through Change practice based on results of | | |
|--|--------------|----|--|---|--|
| Learns and improves via feedback. (PBLI3) | | 12 | Accept and reflect on | | |
| | PBLI3- 01 | 12 | Actively seek and reflect on | feedback from all members of the health care team including faculty, peers, students, nurses, allied health workers, patients and their advocates. | |
| | | 12 | Develop plans for practice improvement based on | | |
| Learns and improves | PBLI4- | 6 | Identify basic knowledge gaps and seek | answer to elinical questions, and parforms self-reflection to incorporate | |
| at the point of care. (PBLI4) | 01 | 12 | In all cases, independently construct and pursue | answers to clinical questions, and performs self-reflection to incorporate learning for future clinical encounters. | |
| () | PBLI4- | 6 | Independently | use(s) technology to manage information (HIPAA compliant), support patient | |
| | 02 | 12 | Teach others to | care decisions using evidence-based medicine and enhance both patient and physician education. | |
| | PBLI4- | 6 | With prompting from faculty | maintains awareness of the situation in the moment, and responds to meet | |
| | 03 | 12 | Independently | situational needs. | |
| | PBLI4- | 12 | Determines applicability of | clinical evidence for individualized patient care. | |
| | 04 | 12 | Customizes management based on | | |

SYSTEMS BASED PRACTICE

| | | | Rheumato | Your Training Program | | |
|---|---------|--|--|--|------------|------------------|
| Subspecialty Reporting Milestone | Number | By this time (months) | The fellow should be able to | For this curricular milestone | Activities | Assessment Tools |
| Works effectively | SBP1-01 | 6 | Acknowledge the contributions from | health care providers from varied disciplines to promote patient contered care | | |
| within an interprofessional team | 2861-01 | 12 | Actively participate and work with | health care providers from varied disciplines to promote patient-centered care. | | |
| (e.g. peers, | | 6 | Recognize the varied | health care providers who work to promote patient safety and to identify risks | | |
| consultants, nursing, | SBP1-02 | 12 | Explain the contributions of | for and strategies to prevent medical errors. | | |
| therapists, nurses, | | 24 | Participate in the activities of | | | |
| home care workers, pharmacists, social | SBP1-03 | 6 | List the individual components that contribute to | appropriate coding based on documentation and reimbursement policies. | | |
| workers and other ancillary professionals and other support | | 18 | Ascribe levels of complexity to the components that comprise | | | |
| personnel). (SBP1) | | 24 | Implement | | | |
| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | SBP1-04 | 6 | Describes | the spectrum of practice models for health care delivery, including the fundamentals of office and personnel management. | | |
| | | 18 | Differentiates among | | | |
| | | 24 | Works effectively within | | | |
| Recognizes system error and advocates for system improvement. | SBP2-01 | Recognize situations leading to 6 inefficiencies, safety concerns and/or preventable medical errors when | | | | |
| (SPB2) | | 12 | Participate in a system level quality improvement initiatives while | partnering with other healthcare teams and professionals to improve the quality of care and patient safety within the system. | | |
| | | 24 | Design and implement a system level | | | |
| | | 12 | quality improvement initiative while Demonstrate ability to | | | |
| | SBP2-02 | 24 | Assist others within one's own system to | recognize opportunities to address causes of disparity in disease and healthcare | | |
| | | 24 | Assist others within one's own system to | delivery. | | |

| | | 24 | Assist the public to | | |
|---|-----------|----|--|---|--|
| Identifies factors that | | 6 | Recognize the necessity to integrate | cost awareness and cost benefit analysis for disease specific care as well as in individual patients. | |
| impact the cost of | SBP3-01 | 18 | Participate in decisions that reflect | | |
| health care, and advocates for, and | 2863-01 - | 24 | Independently incorporate considerations of | | |
| practices cost-effective | | 6 | Recognize | | |
| care. (SBP3) | SBP3-02 | 18 | Identify ways to address | barriers impacting patient care, including socio-economic factors, healthcare | |
| | 3DP3-02 | 18 | Advocate for change of | literacy, medical disability and health care insurance coverage. | |
| | | 24 | Implement measures to correct | | |
| | | 6 | Identify | the various health care settings (academic/public/private/VA) and stakeholders in the healthcare economy. | |
| | SBP3-03 | 18 | Describe the impact on health care cost and access by | | |
| | | 24 | Leverage the advantages, for individual patients, of | | |
| Transitions patients effectively within and across health delivery systems. (SBP4) | | 6 | Identify the providers, therapies, and potential obstacles to successfully | coordinate care across multiple delivery systems, including ambulatory, subacute, acute, rehabilitation and skilled nursing facilities. | |
| | SBP4-01 | 18 | Discuss strategies to overcome the obstacles to successfully | | |
| | | 24 | Implement strategies to successfully | | |

INTERPERSONAL AND COMMUNICATION SKILLS

| | | | Rheumatol | Your Training Program | | |
|---|---------|-----------------------------|--|--|------------|------------------|
| Subspecialty Reporting Milestone | Number | By this time (months) | The fellow should be able to | For this curricular milestone | Activities | Assessment Tools |
| Communicates effectively with patients | ICS1-01 | 6 | Use nonverbal skills, and without interruption | listen carefully to patients and caregivers to create rapport and build a therapeutic relationship. | | |
| and caregivers. (ICS1) | | 6 | Ask thoughtful questions based on ability to | | | |
| | | 6 | Use plain language, avoiding technical medical terms, to | | | |
| | ICS1-02 | 6 | Appropriately use an interpreter to | explain and counsel patients and caregivers about their problems, proposed examinations and treatments, and findings. | | |
| | | 12 | Encourage questions, answering clearly, incorporating new insights to | examinations and treatments, and minings. | | |
| | ICS1-03 | 6 | Recognize the need to incorporate patient preferences to | share decision-making in both diagnostic and therapeutic scenarios. | | |
| | | 12 | Incorporate patient preferences to | | | |
| | | 18 | Solicit and incorporate patient preferences surrounding uncomplicated situations to | | | |
| | | 24 | Solicit and incorporate patient preferences surrounding ambiguous or controversial situations to | | | |
| | | 6 | Demonstrate sensitivity to | | | |
| | ICS1-04 | 12 | Actively seek to understand | differences in patients including, but not limited to race, culture, gender, sexual | | |
| | | 18 | Integrate into evaluation and management plans | orientation, socioeconomic status, literacy, religious beliefs. | | |
| Communicates effectively in | ICS2-01 | 6 | Describe the importance of | communication with other healthcare providers in order to maintain appropriate continuity during transitions of care, including from pediatric to | | |
| interprofessional teams | | 12 | Proactively initiate | adult rheumatology care. | | |

| (e.g., with peers, consultants, nursing, ancillary professionals, and other support personnel). (ICS2) | ICS2-02 | 6 12 18 18 | Recognize the roles and acknowledge the contributions of individuals in support of Interact, adapting and shifting roles as necessary, in support of Initiate problem solving for Assume a leadership role in the education of all members in support of | productive interaction within interprofessional teams. |
|--|---------|---------------------|--|---|
| | | 6 | Utilize common technologies for | |
| | ICS2-03 | 18 | Tailor topic selection, presentation technology, and verbal and nonverbal skills for | effective presentation for the specific audience. |
| | | 24 | Role model proficiency in tailored topic selection, presentation technology, and verbal and nonverbal skills for | |
| Appropriate utilization and completion of | | 6 | Document through templates/scripts to create | |
| health records. (ICS3) | ICS3-01 | 12 | Adjust communication on the basis of context, audience and/or situation for relevant and succinct, | timely and legible authentic documentation that includes a differential diagnosis and clinical reasoning, and support for the appropriate level of reimbursement. |
| | | 18 | Organize complex cases into relevant and succinct, | |

PROFESSIONALISM

| | | | Rheumatol | Your Training Program | | |
|--|--------------------|------------|--|---|------------|------------------|
| Subspecialty Reporting Milestone | Number | Activities | Activities | For this curricular milestone | Activities | Assessment Tools |
| Has professional and respectful interactions with patients, caregivers, and | PROF1- 01 | 12 | Recognize and manage differences of opinion with patients to Recognize and manage differences of opinion with other members of the | demonstrate respectful professional interactions. | | |
| members of the interprofessional team (e.g., peers, consultants, nursing, ancillary | PROF1- | 12 | interprofessional team to Provide constructive feedback to other members of the health care team to | | | |
| professionals, and support personnel). (PROF1) | 02 PROF1- 03 | 6 | Provide responsible team leadership to Recognize, respond to, and report impairment in colleagues or substandard care via peer review process | demonstrate respect for patient dignity and autonomy. as a demonstration of commitment to providing safe patient care. | | |
| Accepts responsibility and follows through on tasks. (PROF2) | PROF2- 01 | 6 | Recognize the scope of his/her abilities and ask for supervision and assistance appropriately When indicated, identify and assist | as demonstration of personal accountability. | | |
| | | 6 | colleagues in need of assistance in the provision of duties | | | |
| | | 12 | Through his/her actions, serve as a professional role model for peers and learners Contribute to the fiscally sound practice of | | | |
| | | 24 | an office | | | |

| ſ | 1 | 1 | | |
|--|--------------|----|--|--|
| | | 1 | Demonstrates appropriate professional appearance | |
| | | 6 | Respond promptly and appropriately to clinical responsibilities including but not limited to calls and pages | |
| | PROF2- 02 | 6 | Carry out timely interactions with colleagues, patients, and their designated caregivers | as a demonstration of the professional attribute of accessibility. |
| | | 12 | Ensure prompt completion of clinical, administrative, curricular and research- related tasks | |
| Responds to each | | 6 | Represent individual patient needs | |
| patient's unique characteristics and | PROF3- | | Show empathy and compassion to all patients | |
| needs. (PROF3) | 01 | 12 | Address disparities in health care among populations that may impact patient care | as a demonstration of being an advocate for all patients. |
| | | 6 | Take responsibility for situations where public health supersedes individual privacy (e.g. reportable infectious diseases) | |
| | PROF3- | 6 | Treat patients with dignity, civility and respect, regardless of race, culture, gender, sexual orientation, socioeconomic status, literacy, and religious beliefs | as a demonstration of showing compassion and respect to patients. |
| | 02 | 6 | Make efforts to support (physical, | as a demonstration of showing compassion and respect to patients. |
| Exhibits integrity and ethical behavior in | PROF4- | 6 | Document and report clinical and research information truthfully | |
| professional conduct. | | 6 | Follow formal policies | |
| (PROF4) | | 6 | Accept personal errors and honestly acknowledge them | |
| | 01 | 6 | Maintain patient confidentiality | as a demonstration of adhering to basic ethical principles. |
| | | 6 | Uphold ethical expectations of clinical, scholarly activity and research including maintenance of up-to-date certifications for all professional activities | |
| | | 6 | Maintain and monitor patient care relationships with colleagues, members of the interprofessional team and office staff to | |
| | PROF4- 02 | 6 | appropriately to manage conflicts of interest. | manage conflicts of interest. |
| | | 6 | Maintain ethical relationships with industry to | |
| | | 6 | Addresses personal, psychological, and physical limitations that may affect professional performance to | |

AMERICAN COLLEGE OF RHEUMATOLOGY

Curriculum Subcommittee Subcommittee of the ACR Committee on Rheumatology Training and Workforce Issues Roster 2019-2020

<u>Chair</u>

Lisa Criscione-Schreiber, MD, MEd (2014-2021) Duke University School of Medicine Box 3490 DUMC Durham, NC, 27710 Email: <u>lisa.criscione@duke.edu</u>

Narender Annapureddy, MD (2018-2021)

Vanderbilt University – Rheumatology 1161 21st Avenue S Nashville, TN. 37203 Email: <u>narender.annapureddy@vanderbilt.edu</u>

Adam Berlinberg, MD (2019-2022)

Fellow-in-Training University of Colorado 550 E. 12th Ave Denver, CO 80203, US Email: adam.berlinberg@ucdenver.edu

Christopher Collins, MD (2018-2020)

Georgetown University Hospital/Washington Hospital Center 110 Irving St. NW. Rm 2A-52 Washington, DC. 20010 Email: <u>chriscollinsmd@hotmail.com</u>

Chase Correia, MD (2017-2020)

Northwestern University 3556 South Seeley Avenue Unit 301 Chicago, IL 60609 E-mail: <u>Chase.Correia@northwestern.edu</u>

Sam Dalvi, MD (2017-2020)

University of Alabama at Birmingham Faculty Office Tower, Room 844 1960 6th Ave South Birmingham, AL 35233 Email: sdalvi@uabmc.edu

Sharon Dowell, MD (2018-2021)

Howard University College of Medicine 2041 Georgia Ave NW, Washington, DC 20060 Email: sharon.dowell@Howard.edu

Evelyn Hsieh, MD, MPH (2014-2020)

Yale University School of Medicine 300 Cedar St. TAC 5525 New Haven, CT. 06520 Email: <u>evelyn.hsieh@yale.edu</u>

Kabita Nanda, MD (2017-2020)

Pediatrics Seattle Children's Hospital 4800 Sand Point Way NE, MA.7.110 Seattle, WA 98105 Email: <u>kabita.nanda@seattlechildrens.org</u>

Rochella Ostrowski, MD, MS (2019-2022)

Loyola University 2160 S 1st Ave Maywood, IL 60153 Email: <u>rostrowski@lumc.edu</u>

Lisa Zickuhr, MD (2019-2022)

Washington University/B-JH/SLCH Consortium CB 8045, 660 S Euclid Ave St. Louis, MO 63110 Email: <u>zickuhrl@wustl.edu</u>

ACKNOWLEDGEMENTS

The authors acknowledge and thank the following contributors to the current and past versions of the Core Curriculum Outline:

The Core Curriculum Outline 2006 Training Guidelines & Assessment Subcommittee of the ACR Committee on Rheumatology Training and Workforce Issues for developing the 2006 ACR Core Curriculum, on which the 2015 and 2020 versions of the Core Curriculum Outline are based. Members of the 2006 Training Guidelines & Assessment Subcommittee include David Daikh, MD, PhD (Chair), Richard D. Brasington, Jr., MD, Andre Barkhuizen, MD, Winn Chatham, MD, Howard Fuchs, MD, Gloria Higgins, PhD, MD, Neal Roberts, MD, Arthur Weinstein, MD, Ernesto Zatarain, MD, and Deirdre Lynch, PhD (ACGME Invited Guest).

The Next Accreditation System Working Group of the ACR Committee of Rheumatology Training and Workforce Issues for developing the 2015 Core Curriculum Outline, on which the 2020 version of the Core Curriculum Outline is based. Members of the Next Accreditation System Working Group included Marcy B. Bolster, MD (Co-Chair), Calvin R. Brown Jr, MD (Co-Chair), Lisa Criscione-Schreiber, MD, MEd, Howard Fuchs, MD, Evelyn Hsieh, MD, PhD, Kenneth S. O'Rourke, MD, Chaim Putterman, MD, Irene J. Tan, MD, and Joanne Valeriano-Marcet, MD.

Past members of Curriculum Subcommittee of the ACR Committee on Rheumatology Training and Workforce Issues who contributed to this revision: Joanne Valeriano-Marcet, MD (Chair 2017-2019), Irene J. Tan, MD, Zachary S. Wallace, MD, Marcy B. Bolster, MD, and Chaim Putterman, MD.

Pediatrics Core Curriculum Outline Stacey Tarvin, FACR,MD,MS, Jennifer Huggins, MD, Tracey Wright, MD, Ashley Cooper, MD, Katherine Marzan, MD, Alisa Gotte, MD, MSc